{"gene":"SERPINA1","run_date":"2026-04-28T20:42:07","timeline":{"discoveries":[{"year":1984,"finding":"Crystal structure of alpha-1-antitrypsin (cleaved form) determined at 3 Å resolution, revealing the polypeptide arranged into three beta-sheets (A, B, C) and eight alpha-helices. The structure showed that Met358 and Ser359 chain ends are on opposite poles of the molecule, indicating a major conformational rearrangement upon cleavage of the reactive center loop. Glu342, mutated to Lys in the Z-variant, was identified in a strategic position for this rearrangement.","method":"X-ray crystallography (isomorphous replacement, cyclic averaging of two crystal forms, crystallographic refinement to R~0.25)","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 — crystal structure at 3 Å, two independent crystal forms, foundational structural paper with 685 citations","pmids":["6332197"],"is_preprint":false},{"year":1982,"finding":"Primary sequence analysis of alpha-1-antitrypsin established its role as a tissue scavenger of leukocyte elastase and showed that two abnormal variants (S and Z) common in Europeans cause deficiency predisposing to emphysema. Cigarette smoking was shown to greatly accelerate the degenerative process by inactivating the reactive center.","method":"Protein sequence determination and variant analysis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — direct protein sequencing with functional interpretation, 609 citations, foundational paper","pmids":["7045697"],"is_preprint":false},{"year":1983,"finding":"Mutation of the active-site Met358 to Arg in the Pittsburgh variant converted alpha-1-antitrypsin from an elastase inhibitor to a thrombin inhibitor (antithrombin activity), establishing Met358 as the reactive center that acts as 'bait' for neutrophil elastase, analogous to Arg393 in antithrombin III acting as bait for thrombin. This confirmed that reactive center identity determines protease specificity.","method":"Characterization of a naturally occurring Met358Arg mutation in a patient with fatal bleeding disorder; plasma protein analysis","journal":"The New England journal of medicine","confidence":"High","confidence_rationale":"Tier 1 — active-site mutation with defined functional switch, replicated across serpin family, 402 citations","pmids":["6604220"],"is_preprint":false},{"year":1984,"finding":"Complete cDNA and gene sequence of alpha-1-antitrypsin determined, revealing a 24-amino acid signal peptide and 394-amino acid mature protein. The S-variant gene was sequenced, identifying a single base substitution (A→T) causing Glu264→Val substitution. The gene structure includes four coding exons and a 5.3 kb intron in the 5' noncoding region.","method":"cDNA cloning and sequencing; gene subcloning and sequencing","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — direct sequencing establishing gene structure and variant molecular basis, 370 citations","pmids":["6093867"],"is_preprint":false},{"year":1988,"finding":"Comprehensive molecular characterization of A1AT established: (1) the protein is a 52-kDa, 394-amino acid globular molecule with nine alpha-helices and three beta-pleated sheets; (2) the active site is centered around Met358 in an external stressed reactive center loop; (3) two critical salt bridges (Glu342-Lys290; Glu263-Lys387) exist within the molecule, and disruption of either causes distinct molecular pathology reducing serum A1AT levels; (4) over 75 variants exist categorized as normal, deficient, dysfunctional, or absent.","method":"Protein structural analysis, molecular biology, restriction fragment analysis, oligonucleotide probing, direct gene sequencing","journal":"The American journal of medicine","confidence":"High","confidence_rationale":"Tier 1-2 — comprehensive structural and molecular characterization, multiple orthogonal methods, 428 citations","pmids":["3289385"],"is_preprint":false},{"year":1996,"finding":"Crystal structure of alpha-1-antitrypsin at 2.9 Å resolution showed the reactive site loop in a stable canonical beta-pleated strand conformation matching that found in all other serine proteinase inhibitor families (Kunitz, Kazal), without loop insertion into the body of the molecule. This favors a two-stage mechanism of inhibition and provides a structural basis for serpin polymerization in disease and for association with beta-amyloid.","method":"X-ray crystallography at 2.9 Å resolution","journal":"Nature structural biology","confidence":"High","confidence_rationale":"Tier 1 — high-resolution crystal structure with functional interpretation, 230 citations","pmids":["8756325"],"is_preprint":false},{"year":2000,"finding":"Crystal structure of a serpin-protease complex revealed the complete mechanism of inhibition: the conformational change is initiated by reaction of the protease's active serine with the serpin reactive center, cleaving it. The cleaved reactive center loop then translocates 71 Å to the opposite pole of the serpin, dragging the tethered protease with it. This causes 37% loss of structure in the protease through distortion of its active site (plucking of the serine from its catalytic triad), preventing release of the protease from the complex and allowing its proteolytic destruction.","method":"X-ray crystallography of serpin-protease complex","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — crystal structure of the inhibitory complex directly revealing mechanism, foundational serpin biology paper with 926 citations","pmids":["11057674"],"is_preprint":false},{"year":2000,"finding":"Oxidation of either Met351 or Met358 in alpha-1-antitrypsin causes loss of anti-neutrophil elastase activity. Both methionines are equally susceptible to hydrogen peroxide oxidation (confirmed by mass spectrometry). Single mutants M351V and M358V showed partial resistance to oxidative inactivation, while the double mutant M351V/M358V was markedly resistant, establishing that oxidation of either residue can inactivate A1AT and providing a mechanism for regulation of A1AT activity at sites of inflammation (e.g., by cigarette smoke).","method":"Site-directed mutagenesis of recombinant A1AT; hydrogen peroxide treatment; mass spectrometry for oxidation site identification; elastase inhibition assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstitution with mutagenesis and MS confirmation, multiple orthogonal methods, 259 citations","pmids":["10867014"],"is_preprint":false},{"year":2000,"finding":"Chemical chaperones, particularly 4-phenylbutyric acid (PBA), mediate increased secretion of functionally active mutant Z alpha-1-antitrypsin (alpha1-ATZ) from the ER. Oral administration of PBA to PiZ transgenic mice increased blood levels of human alpha-1-AT to 20-50% of normal levels, demonstrating that pharmacological intervention in ER retention of misfolded Z-A1AT is possible.","method":"Cell culture model (secretion assay); in vivo oral administration to PiZ transgenic mice; functional activity assessment","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — in vitro and in vivo orthogonal evidence, 338 citations","pmids":["10677536"],"is_preprint":false},{"year":1990,"finding":"Neutrophil collagenase (MMP-8) is capable of cleaving and inactivating alpha-1-antitrypsin. Purified collagenase cleaved A1AT at almost twice the rate at which it cleaved type I collagen. Neutrophil gelatinase also cleaved A1AT but slowly. This was demonstrated by co-fractionation of collagenase and A1AT-cleaving activities by SDS-PAGE and confirmed with purified collagenase preparations, establishing metalloproteinase-mediated inactivation of the primary neutrophil elastase inhibitor.","method":"Preparative SDS-PAGE fractionation of neutrophil supernatant; incubation with purified substrates; Western blot; purified collagenase activity assay; inhibitor studies with 1,10-phenanthroline","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 — purified enzyme reconstitution with substrate, inhibitor validation, multiple approaches, 92 citations","pmids":["2173552"],"is_preprint":false},{"year":1990,"finding":"Prostate-specific antigen (PSA) forms stable SDS-stable complexes with alpha-1-antichymotrypsin (but also interacts with alpha-2-macroglobulin) when added to normal blood plasma in vitro. PSA cleaves the inhibitor at a position identical to that reported for chymotrypsin-alpha-1-antichymotrypsin reaction, demonstrating that A1AT-family serpins can form covalent inhibitory complexes with serine proteases via standard serpin mechanism.","method":"In vitro complex formation with purified proteins; SDS-PAGE; plasma incubation experiments","journal":"European journal of biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro reconstitution with purified proteins; primarily about PSA/alpha-1-antichymotrypsin but demonstrates serpin inhibitory mechanism, 572 citations","pmids":["1702714"],"is_preprint":false},{"year":1994,"finding":"Alveolar epithelial cells (human A549 cell line and rat type-II pneumocytes) synthesize and secrete alpha-1-antitrypsin with modified glycosylation compared to serum AAT. The secreted A1AT retains the ability to form complexes with neutrophil elastase, establishing alveolar epithelial cells as a local source of A1AT for antiprotease defense within the lung.","method":"Northern blot for mRNA; immunoreactive AAT measurement by ELISA; complex formation assay with neutrophil elastase","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal methods (mRNA, secretion, functional assay) in two cell types","pmids":["8013628"],"is_preprint":false},{"year":1996,"finding":"Neutrophils store alpha-1-antitrypsin intracellularly and release it concordantly with neutrophil elastase (NE) upon surface stimulation. Flow cytometry showed decreased intracellular A1AT after stimulation with cytochalasin B/fMLP. Radiolabeling and immunoprecipitation demonstrated increased secretion of A1AT from stimulated neutrophils, with some secreted A1AT forming complexes with NE. This establishes an intrinsic mechanism by which neutrophils dampen the local effects of their own most powerful proteolytic enzyme.","method":"Immunofluorescence; quantitative flow cytometry; [35S]methionine labeling and immunoprecipitation; surface stimulation with cytochalasin B/fMLP","journal":"American journal of respiratory and critical care medicine","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal methods demonstrating storage and release with functional complex formation","pmids":["8970377"],"is_preprint":false},{"year":2002,"finding":"Alpha-1-antitrypsin deficiency and the serpinopathies are characterized by pathological polymerization of mutant A1AT (Z variant, Glu342Lys) within the ER of hepatocytes, forming ordered polymers that cause liver disease while reduced circulating A1AT causes lung disease. The Z mutation disrupts the critical Glu342-Lys290 salt bridge, destabilizing the molecule and promoting polymer formation via aberrant beta-sheet interactions.","method":"Review synthesizing structural, cell biological, and molecular genetic data on serpin polymerization","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 — synthesis of multiple experimental datasets on polymerization mechanism, 212 citations","pmids":["12464660"],"is_preprint":false},{"year":2003,"finding":"A hydrophobic surface cavity in alpha-1-antitrypsin on strand 2 of beta-sheet A (around residues Thr114, Gly117, Leu100) was identified as a target for preventing polymer formation. Mutations Thr114→Phe and Gly117→Phe significantly raised the melting temperature and retarded polymer formation without affecting inhibitory activity, while Leu100→Phe accelerated polymerization. Thr114→Phe reduced polymer formation and increased secretion of Z-A1AT from Xenopus oocytes. Cysteine mutants in the cavity could bind fluorophores, confirming accessibility.","method":"Site-directed mutagenesis; thermal stability assay; polymerization assay; Xenopus oocyte expression system; fluorophore binding to cysteine mutants","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis with multiple functional readouts (stability, polymerization, secretion, ligand binding) in multiple systems","pmids":["12807889"],"is_preprint":false},{"year":2006,"finding":"Serpina1 (alpha-1-antitrypsin) acts as a potent inhibitor of IL-8-induced hematopoietic stem cell (HSC) and hematopoietic progenitor cell (HPC) mobilization. After low-dose total-body irradiation (0.5 Gy), Serpina1 mRNA and protein increased in bone marrow extracellular extracts. Antibody neutralization of Serpina1 reversed inhibitory activity. Exogenous Serpina1 administration almost completely inhibited HSC/HPC mobilization, while heat-inactivated Serpina1 had no effect, demonstrating that elastase-inhibitory activity is required for this function.","method":"In vivo mouse model; bone marrow extract biochemistry; anti-Serpina1 antibody neutralization; exogenous protein administration; heat inactivation control","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — multiple in vivo and ex vivo approaches with antibody neutralization and heat-inactivation controls, 54 citations","pmids":["16432201"],"is_preprint":false},{"year":2008,"finding":"OS-9 (an ER-resident lectin) and GRP94 (ER chaperone) deliver mutant alpha-1-antitrypsin (Z variant) to the Hrd1-SEL1L ubiquitin ligase complex for ER-associated degradation (ERAD). OS-9 binds ERAD substrates and, through the SEL1L adaptor, connects to Hrd1. GRP94, together with Hrd1 and SEL1L, is required for degradation of mutant alpha-1-antitrypsin, placing Z-A1AT degradation in a defined ERAD pathway.","method":"Co-immunoprecipitation; RNAi knockdown; protein degradation assays in mammalian cells","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP with functional knockdown validation, 419 citations","pmids":["18264092"],"is_preprint":false},{"year":2009,"finding":"Alpha-1-antitrypsin is internalized by primary rat lung microvascular endothelial cells via clathrin-mediated (not caveolae-mediated) endocytosis. A1AT associates with clathrin heavy chains but not caveolin-1 at the plasma membrane. Inhibition of clathrin-mediated endocytosis profoundly decreased A1AT internalization and reversed its antiapoptotic action. Cigarette smoke exposure significantly inhibited A1AT uptake in endothelial cells and in mouse lung in vivo, and altered intracellular distribution of clathrin heavy chains.","method":"Specific pharmacological inhibition of endocytic pathways; co-immunoprecipitation with clathrin heavy chain and caveolin-1; in vitro and in vivo (mouse) cigarette smoke exposure; apoptosis assay","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 — pathway-specific inhibition with functional readout, biochemical binding, in vitro and in vivo validation, 48 citations","pmids":["19423638"],"is_preprint":false},{"year":2009,"finding":"Serpina1 protein in bone marrow extracellular fluid is predominantly produced by osteoblasts (OB), not hematopoietic cells. Quantitative RT-PCR showed high Serpina1 mRNA in OB; Western blot confirmed Serpina1 secretion by OB but not by hematopoietic cells; immunohistochemistry localized Serpina1 protein to OB lining the bone. This establishes that Serpina1 is synthesized in the osteoblastic stem cell niche and may regulate HSC maintenance.","method":"Quantitative RT-PCR; Western blot; immunohistochemistry on bone marrow sections","journal":"Experimental hematology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal methods (mRNA, protein, localization) establishing cellular source","pmids":["19375654"],"is_preprint":false},{"year":2010,"finding":"Glycosylated AAT directly binds IL-8 (a CXCR1 ligand), and AAT-IL-8 complex formation prevents IL-8 interaction with CXCR1, thereby inhibiting CXCR1-mediated neutrophil chemotaxis. Additionally, AAT controls soluble immune complex (sIC)-induced neutrophil chemotaxis by inhibiting ADAM-17 enzymatic activity, thereby maintaining membrane expression of the GPI-anchored Fc receptor FcγRIIIb. These two distinct pathways of AAT-mediated neutrophil chemotaxis regulation were confirmed in AAT-deficient patients and restored by augmentation therapy.","method":"Binding assays (AAT-IL-8 complex formation); CXCR1 interaction studies; ADAM-17 enzymatic inhibition assay; FcγRIIIb membrane expression by flow cytometry; human patient samples before/after augmentation therapy","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1-2 — direct binding assay, enzymatic inhibition, human patient validation; multiple orthogonal methods; 235 citations","pmids":["21060150"],"is_preprint":false},{"year":2014,"finding":"A1AT is actively transported (transcytosed) across lung endothelial cells to the alveolar epithelium. Purified A1AT was taken up by confluent endothelial monolayers and secreted both apically and basolaterally. A1AT co-localized with Golgi in endothelium; inhibition of classical secretory pathway increased intracellular retention but promoted non-classical secretion via microparticle release. Polymerized A1AT or cigarette smoke extract impaired transcytosis. In vivo evidence was obtained by two-photon intravital microscopy in mice.","method":"Polarized transwell co-culture; confocal time-lapse microscopy; Golgi inhibition (tunicamycin); two-photon intravital microscopy in mice; microparticle analysis","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — in vitro and in vivo orthogonal approaches with mechanistic pathway manipulation, 42 citations","pmids":["24743137"],"is_preprint":false},{"year":2015,"finding":"Scavenger receptor B type I (SR-BI) mediates A1AT endocytosis by pulmonary endothelial cells. SR-BI immunoprecipitation identified binding to A1AT at the plasma membrane. Knockdown of SCARB1 expression, pretreatment with SR-B ligands (HDL or LDL), or neutralizing SR-BI antibodies reduced A1AT uptake by 30-50%. Scarb1 null mice exhibited decreased lung A1AT content following systemic A1AT administration and reduced anti-inflammatory effects of A1AT during cigarette smoke exposure. Transmission electron microscopy confirmed A1AT endocytosis in both clathrin-coated vesicles and caveolae.","method":"SR-BI immunoprecipitation; siRNA knockdown; competitive ligand pretreatment; neutralizing antibodies; Scarb1 knockout mice; transmission electron microscopy with colloidal gold-labeled A1AT","journal":"American journal of physiology. Lung cellular and molecular physiology","confidence":"High","confidence_rationale":"Tier 2 — receptor identification by Co-IP, knockdown, KO mice, and EM, multiple orthogonal methods, 18 citations","pmids":["26092999"],"is_preprint":false},{"year":2016,"finding":"NQO1 (NAD(P)H:quinone oxidoreductase 1) acts as an RNA-binding protein that binds the 3'UTR and coding region of SERPINA1 mRNA and enhances its translation without affecting mRNA levels. NQO1 silencing decreased polysome size on SERPINA1 mRNA and lowered A1AT protein abundance. Luciferase reporter analysis confirmed regulation through the SERPINA1 3'UTR. NQO1-knockout mice had reduced hepatic and serum A1AT levels and increased neutrophil elastase activity.","method":"RNP immunoprecipitation (RIP) and microarray; biotin pulldown of SERPINA1 mRNA regions; polysome profiling; luciferase reporter assay; NQO1 siRNA knockdown; NQO1-KO mice","journal":"Free radical biology & medicine","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods (RIP, pulldown, polysome profiling, reporter, KO mice), in vitro and in vivo","pmids":["27515817"],"is_preprint":false},{"year":2017,"finding":"The coding variant V213A (rs568223361) in SERPINA1 modulates AAT interaction with neutrophil elastase (NE) in lipoprotein-containing plasma. Quantitative microscale thermophoresis showed M1(A213) AAT has an almost twofold lower dissociation constant with NE in lipoprotein-containing (but not lipid-free) plasma. Hydrogen/deuterium exchange mass spectrometry revealed significant differences in global flexibility between V213 and A213 variants. The Val-213 variant shows stronger lipoprotein interaction and reduced global flexibility, improving local availability and reducing proteolytic inactivation by other proteases in atherosclerotic plaques.","method":"Quantitative microscale thermophoresis; hydrogen/deuterium exchange coupled mass spectrometry","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — two orthogonal biophysical methods (MST binding kinetics, H/D exchange MS) with mechanistic interpretation","pmids":["28265093"],"is_preprint":false},{"year":2017,"finding":"The Trento variant of AAT (E75V) shows non-classical polymerization behavior distinct from Z (E342K) and S (E264V) variants. Trento AAT is efficiently secreted in cellular models but has compromised conformational stability. PAGE and ELISA revealed oligomeric species with different electrophoretic and immunorecognition profiles, including reduced recognition by conformational monoclonal antibodies 2C1 and 4B12. Structural analysis localized the 2C1 epitope between helices E and F and indicated that E75V disrupts a stabilizing interaction between helix C and the post-helix I loop, causing polymer formation through a different structural pathway.","method":"Cell expression models; PAGE; conformational antibody ELISA; epitope mapping; structural analysis","journal":"The FEBS journal","confidence":"Medium","confidence_rationale":"Tier 2 — conformational antibody mapping, structural analysis, multiple biochemical assays in cell models","pmids":["28504839"],"is_preprint":false},{"year":1994,"finding":"Acetaldehyde (at 0.3–1.2 M concentrations) inhibits the anti-elastase activity of alpha-1-antitrypsin in biochemical assays, while equivalent concentrations of ethanol have no effect on elastase activity or A1AT function. This provides a biochemical mechanism by which alcohol metabolism may compound A1AT deficiency.","method":"In vitro elastase inhibition assay with purified A1AT and acetaldehyde/ethanol","journal":"Alcohol (Fayetteville, N.Y.)","confidence":"Low","confidence_rationale":"Tier 3 — single in vitro biochemical assay, supra-physiological acetaldehyde concentrations","pmids":["8060517"],"is_preprint":false},{"year":2000,"finding":"Sodium citrate at low concentrations increases the conformational stability of alpha-1-antitrypsin without affecting inhibitory activity, as demonstrated by a 1.8 M increase in midpoint of guanidine hydrochloride-induced unfolding and ~30-fold decrease in heat inactivation rate at 0.5 M citrate. Citrate also increased the insertion rate of exogenous reactive-center loop peptide into the A beta-sheet, indicating structural changes in the sheet region despite unaltered tertiary structure by fluorescence and CD spectroscopy.","method":"Guanidine hydrochloride denaturation; heat inactivation kinetics; fluorescence spectroscopy; circular dichroism; exogenous peptide insertion assay; chymotrypsin inhibition assay","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 1 — multiple biophysical assays on purified protein revealing conformational mechanism","pmids":["10962087"],"is_preprint":false},{"year":2017,"finding":"Carbamylated alpha-1-antitrypsin (Ca-A1AT) is an antigenic target of anti-carbamylated protein (anti-CarP) antibodies in rheumatoid arthritis patients. A1AT contains multiple surface lysines that are readily carbamylated. Mass spectrometry identified carbamylated A1AT in synovial fluid of an RA patient. This establishes A1AT as a post-translationally modified autoantigen in RA via carbamylation.","method":"Ion exchange chromatography fractionation; mass spectrometry for carbamylated protein identification; ELISA; synovial fluid mass spectrometry","journal":"Journal of autoimmunity","confidence":"Medium","confidence_rationale":"Tier 2 — MS identification of modification site, patient sample confirmation, ELISA validation","pmids":["28291659"],"is_preprint":false},{"year":2022,"finding":"The 5'-UTR of SERPINA1 NM_000295.4 transcript folds into a well-defined multi-helix structural domain that optimizes translation by promoting accessibility at the translation initiation site. Systematic destabilization of mRNA structure across the 5'-UTR showed that most structure-destabilizing mutations had no effect on or decreased translation despite disrupting local structure, because they retained global 5'-UTR structure. Mutations disrupting the helix anchoring the 5'-UTR domain created non-native structures forming a stable helix near the translation initiation site that decreases translation.","method":"SHAPE quantification of RNA structure; systematic mutagenesis across 5'-UTR; cap-dependent translation reporter assays; RNA structure analysis","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 — systematic mutagenesis combined with SHAPE structure probing and translation reporter assays, multiple orthogonal approaches","pmids":["36107773"],"is_preprint":false},{"year":2021,"finding":"miR-320c directly inhibits SERPINA1 expression in hepatic HepG2 cells via binding sites in the 3'UTR region of SERPINA1 mRNA. Overexpression of miR-320 family members in HepG2 cells led to inhibition of SERPINA1 expression. LPS treatment of HL60 cells increased miR-320c expression, suggesting inflammation-mediated regulation of A1AT through this miRNA.","method":"miRNA overexpression in HepG2 cells; quantitative PCR; LPS stimulation of HL60 cells; correlation with patient samples","journal":"Archivos de bronconeumologia","confidence":"Medium","confidence_rationale":"Tier 3 — overexpression experiment in cell line with functional readout, replicated in two publications (PMID 35698951 and 32439252)","pmids":["35698951","32439252"],"is_preprint":false},{"year":2024,"finding":"Hepatic SerpinA1/A1AT functions as a hepatokine that improves energy and glucose metabolism by: (1) inducing proliferation of white and brown preadipocytes; (2) increasing UCP1 expression to promote mitochondrial activation in adipocytes; (3) forming a complex with the Eph receptor B2 (EphB2) and regulating its downstream signaling in adipocytes. Liver-specific SerpinA1 transgenic mice showed increased adipose browning, energy expenditure, and improved glucose tolerance. SerpinA1 knockout mice had decreased adipocyte mitochondrial function, impaired thermogenesis, obesity, and systemic insulin resistance.","method":"Liver-specific transgenic mice; SerpinA1 knockout mice; co-immunoprecipitation (SerpinA1-EphB2 complex); in vitro preadipocyte proliferation and UCP1 assays; metabolic phenotyping","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — receptor identified by Co-IP, transgenic and KO mouse phenotyping, in vitro mechanistic assays, multiple orthogonal methods","pmids":["39532838"],"is_preprint":false},{"year":2025,"finding":"Hepatic A1AT controls the PR3/IL-32γ axis during MASH (metabolic dysfunction-associated steatohepatitis). In MASH, Kupffer cell-derived IL-1β transcriptionally inhibits A1AT expression via HNF4α. Loss of A1AT increases activity of proteinase 3 (PR3), a proinflammatory protease from monocyte-derived Kupffer cells. PR3 cleaves IL-32γ, converting it from an anti-inflammatory/antifibrogenic cytokine into a potent activator of Kupffer cells and failing to prevent hepatic stellate cell activation. In quintuple Serpina1a-e knockout mice, A1AT ablation worsened MASH; A1AT restoration or PR3 inhibition mitigated MASH. A PR3-resistant IL-32γ V104A mutation sustained IL-32γ's protective anti-MASH effects.","method":"Quintuple Serpina1a-e knockout mice; fast-food diet MASH model; cytokine array with PR3; IL-32γ V104A mutation; in vivo IL-32γ overexpression; A1AT/PR3 inhibitor treatment; hepatic stellate cell activation assays","journal":"Experimental & molecular medicine","confidence":"High","confidence_rationale":"Tier 1-2 — KO mice, pathway-specific mutations, substrate identification by cytokine array, multiple in vivo and in vitro orthogonal approaches","pmids":["39939782"],"is_preprint":false},{"year":2024,"finding":"CEBPB transcription factor binds the SERPINA1 gene promoter and promotes its transcription, as demonstrated by ChIP and luciferase reporter assays. Overexpression of SERPINA1 in colorectal cancer cells induces nuclear translocation and phosphorylation of the p65 subunit through the PI3K/Akt/NF-κB pathway, promoting cell migration and proliferation. Knockdown of SERPINA1 attenuated PI3K/Akt/NF-κB signaling.","method":"ChIP assay; luciferase reporter assay; SERPINA1 overexpression and knockdown; PI3K/Akt/NF-κB pathway analysis; in vitro migration/invasion assays; in vivo liver metastasis model","journal":"Cell death discovery","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP and reporter gene confirm transcriptional regulation; pathway placement by OE/KD with signaling readouts","pmids":["38710698"],"is_preprint":false},{"year":2022,"finding":"In trophoblast-derived HTR8/SVneo cells, siRNA knockdown of SERPINA1 revealed marked effects on regulation of the actin cytoskeleton pathway, Slit-Robo signaling, and extracellular matrix organization. Immunoelectron microscopy localized A1AT in villous trophoblasts and in decidual fibrinoid deposits in association with specific extracellular proteins, establishing a role for A1AT beyond protease inhibition in maintaining placental structural integrity.","method":"siRNA knockdown in HTR8/SVneo cells; pathway analysis; immunoelectron microscopy; placental proteomics and exon sequencing","journal":"BMC medicine","confidence":"Medium","confidence_rationale":"Tier 2 — siRNA KD with defined pathway readouts, subcellular localization by immunoEM","pmids":["35477570"],"is_preprint":false},{"year":2021,"finding":"In vitro, intra-articular and systemic administration of AAT reversed joint inflammation, nociception, and cartilage degradation in murine arthritis models. SERPINA1 transfection and recombinant AAT protein promoted chondrogenic differentiation in human chondrocytes through activation of PKA-dependent CREB signaling and inhibition of Wnt/β-catenin pathways, establishing a direct mechanistic pathway for AAT's chondroprotective effects.","method":"SERPINA1 transfection; recombinant AAT protein treatment; PKA/CREB signaling assays; Wnt/β-catenin pathway analysis; gene expression analysis (col2a1, acan, sox9, mmp13, adamts5); in vivo murine arthritis models","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 — transfection and recombinant protein with defined signaling pathway readouts in vitro, confirmed in vivo","pmids":["33788977"],"is_preprint":false},{"year":1981,"finding":"Alpha-1-antitrypsin inactivates urinary kallikrein, as demonstrated by an inverse relationship (r=0.84) between kallikrein activity and urinary A1AT concentration in patient samples, establishing renal kallikrein as a substrate/target of A1AT.","method":"Clinical urinary proteolytic activity assay (azocasein substrate with kallikrein); immunoassay for urinary A1AT; correlation analysis in 100 hypertensive/proteinuric/hematuria patients","journal":"Klinische Wochenschrift","confidence":"Low","confidence_rationale":"Tier 3 — correlational clinical data, no direct in vitro enzyme inhibition assay with purified components","pmids":["6973046"],"is_preprint":false}],"current_model":"SERPINA1 encodes alpha-1-antitrypsin (A1AT), a 52-kDa serpin whose crystal structure revealed a reactive center loop (RCL) containing Met358 as the elastase 'bait'; upon protease attack, the RCL translocates 71 Å carrying the tethered protease and inducing 37% loss of protease structure to prevent its release—the canonical serpin suicide-inhibitor mechanism. Oxidation of Met351 or Met358 abolishes elastase inhibition, explaining cigarette-smoke inactivation. The Z-variant (E342K) disrupts a salt bridge, causing ER retention and polymerization via the Hrd1/SEL1L/OS-9/GRP94 ERAD pathway; chemical chaperones can partially reverse this ER retention. Beyond elastase inhibition, A1AT directly binds IL-8 to block CXCR1 signaling, inhibits ADAM-17 to maintain FcγRIIIb on neutrophil membranes, inhibits proteinase 3 (PR3) to protect IL-32γ from cleavage in the liver, forms a complex with EphB2 to regulate adipocyte UCP1 and preadipocyte proliferation, undergoes clathrin/SR-BI-mediated endocytosis in lung endothelium for transcytosis to alveolar epithelium, and has its mRNA translation enhanced by NQO1 binding its 3'UTR and regulated by a defined 5'-UTR RNA structure."},"narrative":{"teleology":[{"year":1982,"claim":"Establishing A1AT as the primary tissue scavenger of leukocyte elastase and linking the common S and Z deficiency variants to emphysema pathogenesis answered the fundamental question of what protease–antiprotease imbalance drives lung destruction.","evidence":"Protein sequence determination and variant analysis in human plasma","pmids":["7045697"],"confidence":"High","gaps":["Mechanism of inhibition unknown at atomic level","Molecular basis of Z and S variant dysfunction not yet resolved"]},{"year":1983,"claim":"The Pittsburgh variant (Met358→Arg) demonstrated that reactive center identity dictates protease specificity, converting A1AT from an elastase inhibitor to a thrombin inhibitor and establishing the bait-residue paradigm for the entire serpin family.","evidence":"Characterization of a naturally occurring active-site mutation in a patient with fatal bleeding disorder","pmids":["6604220"],"confidence":"High","gaps":["How the conformational change upon cleavage traps the protease was structurally undefined"]},{"year":1984,"claim":"Determination of the crystal structure of cleaved A1AT and the complete gene/cDNA sequence revealed the three β-sheet / eight α-helix architecture, placed Glu342 at a strategic position for the conformational rearrangement (explaining Z-variant pathology), and defined the S-variant as Glu264→Val.","evidence":"X-ray crystallography at 3 Å (two crystal forms) and cDNA/gene sequencing","pmids":["6332197","6093867"],"confidence":"High","gaps":["Native (uncleaved) structure not yet solved","Atomic mechanism of loop translocation unknown"]},{"year":1996,"claim":"The native-form crystal structure at 2.9 Å showed the reactive center loop in a canonical β-strand conformation without insertion into the molecule, supporting a two-stage inhibition mechanism and providing a structural basis for aberrant polymerization.","evidence":"X-ray crystallography at 2.9 Å resolution","pmids":["8756325"],"confidence":"High","gaps":["Full serpin–protease complex structure not yet available","Polymer interface not resolved atomically"]},{"year":2000,"claim":"Three simultaneous advances resolved core mechanism: (1) the serpin–protease complex crystal structure showed the 71 Å loop translocation drags and distorts the tethered protease; (2) mutagenesis/MS established that oxidation of either Met351 or Met358 abolishes elastase inhibition; (3) chemical chaperone PBA rescued Z-A1AT secretion in cells and PiZ mice.","evidence":"Crystal structure of serpin–protease complex; site-directed mutagenesis with mass spectrometry and elastase assays; PBA treatment in cell culture and PiZ transgenic mice","pmids":["11057674","10867014","10677536"],"confidence":"High","gaps":["In vivo relevance of oxidative inactivation at physiological oxidant concentrations not fully tested","Whether PBA corrects polymerization or simply accelerates folding kinetics unresolved"]},{"year":2003,"claim":"Identification of a druggable hydrophobic cavity on β-sheet A (Thr114, Gly117) that, when filled by mutagenesis, stabilized the molecule and retarded polymerization without affecting inhibitory activity, provided the first structure-based target for anti-polymerization small molecules.","evidence":"Site-directed mutagenesis with thermal stability, polymerization kinetics, and Xenopus oocyte secretion assays","pmids":["12807889"],"confidence":"High","gaps":["No small-molecule ligand for the cavity identified","Effect on Z-variant polymerization in hepatocytes not tested"]},{"year":2008,"claim":"Mapping Z-A1AT degradation onto the Hrd1/SEL1L/OS-9/GRP94 ERAD pathway answered how misfolded Z-A1AT is targeted for proteasomal destruction in the ER, explaining the gain-of-toxic-function hepatic disease.","evidence":"Co-immunoprecipitation and RNAi knockdown of ERAD components with Z-A1AT degradation assays in mammalian cells","pmids":["18264092"],"confidence":"High","gaps":["Contribution of autophagy vs. ERAD to Z-polymer clearance not fully delineated","Whether ERAD saturation triggers the inflammatory hepatic response is unclear"]},{"year":2009,"claim":"Discovery that A1AT is internalized by lung endothelial cells via clathrin-mediated endocytosis—and that cigarette smoke inhibits this uptake—established that delivery of circulating A1AT to the lung interstitium requires active receptor-mediated transcytosis rather than passive diffusion.","evidence":"Pharmacological endocytic pathway inhibition, co-IP with clathrin heavy chain, in vivo mouse cigarette smoke exposure","pmids":["19423638"],"confidence":"High","gaps":["Receptor identity for clathrin-dependent uptake not identified at this stage"]},{"year":2010,"claim":"Demonstration that A1AT directly binds IL-8 to block CXCR1 signaling and independently inhibits ADAM-17 to maintain Fcγ RIIIb on neutrophils revealed two protease-independent anti-inflammatory pathways, extending A1AT's function beyond elastase inhibition.","evidence":"Direct binding assays, ADAM-17 enzymatic inhibition, flow cytometry for Fcγ RIIIb; human AAT-deficient patient samples with augmentation therapy","pmids":["21060150"],"confidence":"High","gaps":["Structural basis of A1AT–IL-8 interaction unresolved","Whether ADAM-17 inhibition is direct active-site engagement or allosteric unclear"]},{"year":2015,"claim":"Identification of SR-BI as an endothelial receptor for A1AT uptake, confirmed by knockout mouse phenotype, resolved the receptor question for pulmonary transcytosis and linked A1AT biology to lipoprotein receptor pathways.","evidence":"Co-IP, siRNA knockdown, competitive ligand blocking, Scarb1 KO mice, immunogold EM","pmids":["26092999"],"confidence":"High","gaps":["Whether SR-BI is the sole receptor or acts redundantly with other receptors not resolved","Caveolae vs. clathrin contribution to SR-BI-mediated uptake not fully dissected"]},{"year":2016,"claim":"NQO1 was identified as an RNA-binding protein that binds the SERPINA1 3′-UTR and coding region to enhance A1AT translation, revealing a post-transcriptional regulatory axis confirmed by NQO1-KO mice having reduced serum A1AT and increased elastase activity.","evidence":"RNP immunoprecipitation, biotin pulldown, polysome profiling, luciferase reporters, NQO1-KO mice","pmids":["27515817"],"confidence":"High","gaps":["How NQO1's oxidoreductase activity relates to its RNA-binding function unknown","Other trans-acting factors regulating SERPINA1 mRNA not characterized"]},{"year":2022,"claim":"Systematic SHAPE probing and mutagenesis of the SERPINA1 5′-UTR revealed a structured RNA domain that optimizes cap-dependent translation by maintaining accessibility at the initiation site, adding a cis-regulatory layer to A1AT translational control.","evidence":"SHAPE structure probing, systematic 5′-UTR mutagenesis, cap-dependent translation reporter assays","pmids":["36107773"],"confidence":"High","gaps":["In vivo relevance of 5′-UTR structure under stress conditions not tested","Whether disease-associated variants affect 5′-UTR folding unknown"]},{"year":2024,"claim":"A1AT was shown to function as a hepatokine that complexes with EphB2 to induce adipocyte UCP1 expression and preadipocyte proliferation, establishing an endocrine role in energy metabolism beyond its canonical antiprotease function.","evidence":"Co-IP of A1AT–EphB2 complex; liver-specific transgenic and KO mice with metabolic phenotyping; in vitro adipocyte assays","pmids":["39532838"],"confidence":"High","gaps":["Stoichiometry and structural basis of A1AT–EphB2 complex unknown","Whether this function requires serpin inhibitory activity is untested"]},{"year":2025,"claim":"Identification of the PR3/IL-32γ axis as a hepatic target of A1AT in MASH revealed that Kupffer cell IL-1β suppresses A1AT expression via HNF4α, enabling PR3 to cleave protective IL-32γ, which links A1AT deficiency to steatohepatitis progression.","evidence":"Quintuple Serpina1a-e KO mice, fast-food diet MASH model, PR3-resistant IL-32γ mutant, A1AT restoration experiments","pmids":["39939782"],"confidence":"High","gaps":["Relevance to human MASH with normal A1AT genotype not established","Whether PR3 inhibition fully recapitulates A1AT restoration unclear"]},{"year":null,"claim":"Key unresolved questions include: the atomic structure of A1AT polymers; the structural basis of the A1AT–IL-8 and A1AT–EphB2 interactions; the mechanism by which NQO1's RNA-binding and oxidoreductase activities are coordinated; and whether A1AT's metabolic hepatokine function is serpin-activity dependent or represents an entirely independent molecular surface.","evidence":"","pmids":[],"confidence":"Medium","gaps":["Polymer interface not resolved at atomic level despite decades of effort","No crystal structure of A1AT–EphB2 or A1AT–IL-8 complex","Therapeutic targeting of the β-sheet A cavity not validated in human trials"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,2,4,6,7]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[6,7,15]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[23]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[1,11,12,15,18,19,23]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[8,13,14,16]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[12]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[17,21]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[15,19,31]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[6,16]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[30]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[19,30,32]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[13,31]}],"complexes":[],"partners":["ELANE","CXCL8","ADAM17","EPHB2","PRTN3","NQO1","SCARB1","CLTC"],"other_free_text":[]},"mechanistic_narrative":"SERPINA1 encodes alpha-1-antitrypsin (A1AT), a secreted serpin-family serine protease inhibitor that functions as the principal physiological inhibitor of neutrophil elastase and serves broader roles in immune regulation and metabolic homeostasis. A1AT employs a suicide-inhibitor mechanism in which its reactive center loop, with Met358 as the protease 'bait', is cleaved by the target protease, triggering a 71 Å translocation of the loop that carries the covalently tethered protease to the opposite pole of the molecule, distorting its active site and preventing release [PMID:11057674, PMID:6332197]. Beyond elastase inhibition, A1AT directly binds IL-8 to block CXCR1-mediated neutrophil chemotaxis, inhibits ADAM-17 to preserve Fcγ RIIIb on neutrophil membranes [PMID:21060150], inhibits proteinase 3 to protect anti-inflammatory IL-32γ in the liver [PMID:39939782], and acts as a hepatokine that complexes with EphB2 to promote adipocyte UCP1 expression and energy metabolism [PMID:39532838]. The Z variant (Glu342Lys) disrupts a critical salt bridge, causing ER retention, polymerization via Hrd1/SEL1L/OS-9/GRP94-dependent ERAD, hepatocyte inclusion body disease, and reduced circulating A1AT predisposing to emphysema [PMID:18264092, PMID:6093867, PMID:12464660]."},"prefetch_data":{"uniprot":{"accession":"P01009","full_name":"Alpha-1-antitrypsin","aliases":["Alpha-1 protease inhibitor","Alpha-1-antiproteinase","Serpin A1"],"length_aa":418,"mass_kda":46.7,"function":"Inhibitor of serine proteases. Its primary target is elastase, but it also has a moderate affinity for plasmin and thrombin. Irreversibly inhibits trypsin, chymotrypsin and plasminogen activator. The aberrant form inhibits insulin-induced NO synthesis in platelets, decreases coagulation time and has proteolytic activity against insulin and plasmin Reversible chymotrypsin inhibitor. It also inhibits elastase, but not trypsin. Its major physiological function is the protection of the lower respiratory tract against proteolytic destruction by human leukocyte elastase (HLE)","subcellular_location":"Secreted, extracellular space, extracellular matrix","url":"https://www.uniprot.org/uniprotkb/P01009/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SERPINA1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SERPINA1","total_profiled":1310},"omim":[{"mim_id":"620965","title":"SMALL VCP-INTERACTING PROTEIN; SVIP","url":"https://www.omim.org/entry/620965"},{"mim_id":"617471","title":"SERPIN PEPTIDASE INHIBITOR, CLADE A, MEMBER 12; SERPINA12","url":"https://www.omim.org/entry/617471"},{"mim_id":"616942","title":"PROTEIN DISULFIDE ISOMERASE, FAMILY A, MEMBER 5; PDIA5","url":"https://www.omim.org/entry/616942"},{"mim_id":"613490","title":"ALPHA-1-ANTITRYPSIN DEFICIENCY; A1ATD","url":"https://www.omim.org/entry/613490"},{"mim_id":"609443","title":"CHYMOTRYPSIN-LIKE ELASTASE FAMILY, MEMBER 2A; CELA2A","url":"https://www.omim.org/entry/609443"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Vesicles","reliability":"Enhanced"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"liver","ntpm":31416.7}],"url":"https://www.proteinatlas.org/search/SERPINA1"},"hgnc":{"alias_symbol":["AAT","A1A","PI1","alpha-1-antitrypsin","A1AT","alpha1AT"],"prev_symbol":["PI"]},"alphafold":{"accession":"P01009","domains":[{"cath_id":"3.30.497.10","chopping":"46-215_316-362","consensus_level":"medium","plddt":95.139,"start":46,"end":362},{"cath_id":"2.30.39.10","chopping":"220-312_389-411","consensus_level":"medium","plddt":96.2537,"start":220,"end":411}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P01009","model_url":"https://alphafold.ebi.ac.uk/files/AF-P01009-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P01009-F1-predicted_aligned_error_v6.png","plddt_mean":88.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SERPINA1","jax_strain_url":"https://www.jax.org/strain/search?query=SERPINA1"},"sequence":{"accession":"P01009","fasta_url":"https://rest.uniprot.org/uniprotkb/P01009.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P01009/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P01009"}},"corpus_meta":[{"pmid":"3289385","id":"PMC_3289385","title":"Molecular basis of alpha-1-antitrypsin deficiency.","date":"1988","source":"The American journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/3289385","citation_count":428,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1671425","id":"PMC_1671425","title":"Aerosol alpha 1-antitrypsin treatment for cystic fibrosis.","date":"1991","source":"Lancet (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/1671425","citation_count":302,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17115945","id":"PMC_17115945","title":"Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults.","date":"2006","source":"Human gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/17115945","citation_count":148,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22634722","id":"PMC_22634722","title":"Expanding the clinical indications for α(1)-antitrypsin therapy.","date":"2012","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/22634722","citation_count":126,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19409369","id":"PMC_19409369","title":"Protein-cofactor interactions in bioenergetic complexes: the role of the A1A and A1B phylloquinones in Photosystem I.","date":"2009","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/19409369","citation_count":100,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19074878","id":"PMC_19074878","title":"The high-mobility group A1a/signal transducer and activator of transcription-3 axis: an achilles heel for hematopoietic malignancies?","date":"2008","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19074878","citation_count":94,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2173552","id":"PMC_2173552","title":"Human neutrophil collagenase cleaves alpha 1-antitrypsin.","date":"1990","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/2173552","citation_count":92,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24854541","id":"PMC_24854541","title":"Immune-modulating effects of alpha-1 antitrypsin.","date":"2014","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24854541","citation_count":90,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35748699","id":"PMC_35748699","title":"Fazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency.","date":"2022","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35748699","citation_count":86,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8013628","id":"PMC_8013628","title":"Secretion of alpha 1-antitrypsin by alveolar epithelial cells.","date":"1994","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/8013628","citation_count":68,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21752289","id":"PMC_21752289","title":"The prevalence of alpha-1 antitrypsin deficiency in Ireland.","date":"2011","source":"Respiratory research","url":"https://pubmed.ncbi.nlm.nih.gov/21752289","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18515255","id":"PMC_18515255","title":"SERPINA1 gene variants in individuals from the general population with reduced alpha1-antitrypsin concentrations.","date":"2008","source":"Clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18515255","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34848258","id":"PMC_34848258","title":"Alpha-1 antitrypsin deficiency: A re-surfacing adult liver disorder.","date":"2021","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/34848258","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29597895","id":"PMC_29597895","title":"In Vivo Genome Editing Partially Restores Alpha1-Antitrypsin in a Murine Model of AAT Deficiency.","date":"2018","source":"Human gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/29597895","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14737112","id":"PMC_14737112","title":"High-mobility group A1a protein regulates Ras/ERK signaling in MCF-7 human breast cancer cells.","date":"2004","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/14737112","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33632708","id":"PMC_33632708","title":"Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency.","date":"2021","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/33632708","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32051168","id":"PMC_32051168","title":"α1-Antitrypsin deficiency and chronic respiratory disorders.","date":"2020","source":"European respiratory review : an official journal of the European Respiratory Society","url":"https://pubmed.ncbi.nlm.nih.gov/32051168","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25425243","id":"PMC_25425243","title":"Identification and characterisation of eight novel SERPINA1 Null mutations.","date":"2014","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/25425243","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16432201","id":"PMC_16432201","title":"Serpina1 is a potent inhibitor of IL-8-induced hematopoietic stem cell mobilization.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16432201","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18438953","id":"PMC_18438953","title":"Elevated expression of SerpinA1 and SerpinA3 in HLA-positive cervical carcinoma.","date":"2008","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/18438953","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31661293","id":"PMC_31661293","title":"The Effects of Rare SERPINA1 Variants on Lung Function and Emphysema in SPIROMICS.","date":"2020","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31661293","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16088434","id":"PMC_16088434","title":"A review of alpha-1 antitrypsin deficiency.","date":"2005","source":"Seminars in respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16088434","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12807889","id":"PMC_12807889","title":"Targeting a surface cavity of alpha 1-antitrypsin to prevent conformational disease.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12807889","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32379724","id":"PMC_32379724","title":"Development of an RNAi therapeutic for alpha-1-antitrypsin liver disease.","date":"2020","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/32379724","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19423638","id":"PMC_19423638","title":"Mechanism of alpha-1 antitrypsin endocytosis by lung endothelium.","date":"2009","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/19423638","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11145960","id":"PMC_11145960","title":"A link between apoptosis and degree of phosphorylation of high mobility group A1a protein in leukemic cells.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11145960","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6763344","id":"PMC_6763344","title":"Alpha-1-antitrypsin: an ignored protein in understanding liver disease.","date":"1982","source":"Seminars in liver disease","url":"https://pubmed.ncbi.nlm.nih.gov/6763344","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8706667","id":"PMC_8706667","title":"The Aspergillus nidulans penicillin-biosynthesis gene aat (penDE) is controlled by a CCAAT-containing DNA element.","date":"1996","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8706667","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24743137","id":"PMC_24743137","title":"Active trafficking of alpha 1 antitrypsin across the lung endothelium.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24743137","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28291659","id":"PMC_28291659","title":"Identification of carbamylated alpha 1 anti-trypsin (A1AT) as an antigenic target of anti-CarP antibodies in patients with rheumatoid arthritis.","date":"2017","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/28291659","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28265093","id":"PMC_28265093","title":"Common coding variant in SERPINA1 increases the risk for large artery stroke.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/28265093","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8970377","id":"PMC_8970377","title":"Activated neutrophils secrete stored alpha 1-antitrypsin.","date":"1996","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/8970377","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20955965","id":"PMC_20955965","title":"Alpha-1-antitrypsin deficiency.","date":"2010","source":"Best practice & research. Clinical gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/20955965","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30761929","id":"PMC_30761929","title":"Emphysema: looking beyond alpha-1 antitrypsin deficiency.","date":"2019","source":"Expert review of respiratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30761929","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20049513","id":"PMC_20049513","title":"Protease inhibitor SERPINA1 expression in epithelial ovarian cancer.","date":"2010","source":"Clinical & experimental metastasis","url":"https://pubmed.ncbi.nlm.nih.gov/20049513","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10931199","id":"PMC_10931199","title":"Chemical synthesis and characterization of Pi1, a scorpion toxin from Pandinus imperator active on K+ channels.","date":"2000","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10931199","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3662119","id":"PMC_3662119","title":"Simultaneous phenotyping of pig plasma alpha-protease inhibitors (PI1, PO1A, PO1B, PI2) and four other proteins (PO2, TF, CP, HPX) by a simple method of 2D horizontal electrophoresis.","date":"1987","source":"Animal genetics","url":"https://pubmed.ncbi.nlm.nih.gov/3662119","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27564673","id":"PMC_27564673","title":"Gene Therapy for Alpha-1 Antitrypsin Deficiency Lung Disease.","date":"2016","source":"Annals of the American Thoracic Society","url":"https://pubmed.ncbi.nlm.nih.gov/27564673","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38710698","id":"PMC_38710698","title":"CEBPB-mediated upregulation of SERPINA1 promotes colorectal cancer progression by enhancing STAT3 signaling.","date":"2024","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/38710698","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22912729","id":"PMC_22912729","title":"SERPINA1 PiZ and PiS heterozygotes and lung function decline in the SAPALDIA cohort.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22912729","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33788977","id":"PMC_33788977","title":"Alpha-1-antitrypsin reduces inflammation and exerts chondroprotection in arthritis.","date":"2021","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/33788977","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29045001","id":"PMC_29045001","title":"Anti-inflammaging effects of human alpha-1 antitrypsin.","date":"2017","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/29045001","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17562108","id":"PMC_17562108","title":"Alpha-1-antitrypsin deficiency: current concepts.","date":"2007","source":"Lung","url":"https://pubmed.ncbi.nlm.nih.gov/17562108","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27515817","id":"PMC_27515817","title":"Novel RNA-binding activity of NQO1 promotes SERPINA1 mRNA translation.","date":"2016","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27515817","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24011266","id":"PMC_24011266","title":"Investigation of CCL18 and A1AT as potential urinary biomarkers for bladder cancer detection.","date":"2013","source":"BMC urology","url":"https://pubmed.ncbi.nlm.nih.gov/24011266","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22500781","id":"PMC_22500781","title":"A review of augmentation therapy for alpha-1 antitrypsin deficiency.","date":"2012","source":"Expert opinion on biological therapy","url":"https://pubmed.ncbi.nlm.nih.gov/22500781","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28504839","id":"PMC_28504839","title":"The pathological Trento variant of alpha-1-antitrypsin (E75V) shows nonclassical behaviour during polymerization.","date":"2017","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/28504839","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33824927","id":"PMC_33824927","title":"Alpha-1 antitrypsin deficiency liver disease.","date":"2021","source":"Translational gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/33824927","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29607607","id":"PMC_29607607","title":"Alpha-1-antitrypsin in cell and organ transplantation.","date":"2018","source":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","url":"https://pubmed.ncbi.nlm.nih.gov/29607607","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22414631","id":"PMC_22414631","title":"Fibromyalgia, mood disorders, and intense creative energy: A1AT polymorphisms are not always silent.","date":"2012","source":"Neurotoxicology","url":"https://pubmed.ncbi.nlm.nih.gov/22414631","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35477570","id":"PMC_35477570","title":"Human placental proteomics and exon variant studies link AAT/SERPINA1 with spontaneous preterm birth.","date":"2022","source":"BMC medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35477570","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25723058","id":"PMC_25723058","title":"Diabetic retinopathy: could the alpha-1 antitrypsin be a therapeutic option?","date":"2014","source":"Biological research","url":"https://pubmed.ncbi.nlm.nih.gov/25723058","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32668173","id":"PMC_32668173","title":"Advances in Alpha-1 Antitrypsin Gene Therapy.","date":"2020","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/32668173","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6607204","id":"PMC_6607204","title":"alpha-1-Antitrypsin deficiency.","date":"1984","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/6607204","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34390020","id":"PMC_34390020","title":"SERPINA1, generalized pustular psoriasis, and adult-onset immunodeficiency.","date":"2021","source":"The Journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/34390020","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28364818","id":"PMC_28364818","title":"Liver Transplantation in Alpha-1 Antitrypsin Deficiency.","date":"2017","source":"Clinics in liver disease","url":"https://pubmed.ncbi.nlm.nih.gov/28364818","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11232197","id":"PMC_11232197","title":"Liver injury in alpha 1-antitrypsin deficiency.","date":"2000","source":"Clinics in liver disease","url":"https://pubmed.ncbi.nlm.nih.gov/11232197","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36107773","id":"PMC_36107773","title":"Global 5'-UTR RNA structure regulates translation of a SERPINA1 mRNA.","date":"2022","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/36107773","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31957347","id":"PMC_31957347","title":"CSF SerpinA1 in Creutzfeldt-Jakob disease and frontotemporal lobar degeneration.","date":"2020","source":"Annals of clinical and translational neurology","url":"https://pubmed.ncbi.nlm.nih.gov/31957347","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26092999","id":"PMC_26092999","title":"Scavenger receptor class B, type I-mediated uptake of A1AT by pulmonary endothelial cells.","date":"2015","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/26092999","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26321041","id":"PMC_26321041","title":"SERPINA1 Full-Gene Sequencing Identifies Rare Mutations Not Detected in Targeted Mutation Analysis.","date":"2015","source":"The Journal of molecular diagnostics : JMD","url":"https://pubmed.ncbi.nlm.nih.gov/26321041","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1447962","id":"PMC_1447962","title":"Genetic variants of alpha-1-antitrypsin (AAT).","date":"1992","source":"Liver","url":"https://pubmed.ncbi.nlm.nih.gov/1447962","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28752442","id":"PMC_28752442","title":"Pathophysiology of Alpha-1 Antitrypsin Lung Disease.","date":"2017","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/28752442","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33858475","id":"PMC_33858475","title":"Methylation of SERPINA1 gene promoter may predict chronic obstructive pulmonary disease in patients affected by acute coronary syndrome.","date":"2021","source":"Clinical epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/33858475","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25442121","id":"PMC_25442121","title":"Molecular pathogenesis of alpha-1-antitrypsin deficiency.","date":"2014","source":"Revue des maladies respiratoires","url":"https://pubmed.ncbi.nlm.nih.gov/25442121","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20202861","id":"PMC_20202861","title":"Collective mass spectrometry approaches reveal broad and combinatorial modification of high mobility group protein A1a.","date":"2010","source":"Journal of the American Society for Mass Spectrometry","url":"https://pubmed.ncbi.nlm.nih.gov/20202861","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35698951","id":"PMC_35698951","title":"miR-320c Regulates SERPINA1 Expression and Is Induced in Patients With Pulmonary Disease.","date":"2021","source":"Archivos de bronconeumologia","url":"https://pubmed.ncbi.nlm.nih.gov/35698951","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30078589","id":"PMC_30078589","title":"Acidic polypeptides A1a, A3 and A4 of Gly m 6 (glycinin) are allergenic for piglets.","date":"2018","source":"Veterinary immunology and immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/30078589","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36825473","id":"PMC_36825473","title":"Gene therapy for alpha-1 antitrypsin deficiency: an update.","date":"2023","source":"Expert opinion on biological therapy","url":"https://pubmed.ncbi.nlm.nih.gov/36825473","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19375654","id":"PMC_19375654","title":"Serpina1 (alpha1-AT) is synthesized in the osteoblastic stem cell niche.","date":"2009","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/19375654","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37993348","id":"PMC_37993348","title":"Alpha-1 antitrypsin deficiency.","date":"2023","source":"Medicina clinica","url":"https://pubmed.ncbi.nlm.nih.gov/37993348","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30131830","id":"PMC_30131830","title":"Update on α1-antitrypsin deficiency.","date":"2018","source":"Breathe (Sheffield, England)","url":"https://pubmed.ncbi.nlm.nih.gov/30131830","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37236906","id":"PMC_37236906","title":"Alpha-1 antitrypsin deficiency and Pi*S and Pi*Z SERPINA1 variants are associated with asthma exacerbations.","date":"2024","source":"Pulmonology","url":"https://pubmed.ncbi.nlm.nih.gov/37236906","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28486562","id":"PMC_28486562","title":"Exogenous alpha 1-antitrypsin down-regulates SERPINA1 expression.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28486562","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2117160","id":"PMC_2117160","title":"Discovery of alpha 1-antitrypsin deficiency.","date":"1990","source":"Lung","url":"https://pubmed.ncbi.nlm.nih.gov/2117160","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1859394","id":"PMC_1859394","title":"The molecular genetics of alpha 1 antitrypsin deficiency.","date":"1991","source":"BioEssays : news and reviews in molecular, cellular and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/1859394","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3264243","id":"PMC_3264243","title":"Neonatal screening for alpha-1-antitrypsin deficiency.","date":"1988","source":"European journal of pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/3264243","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39401571","id":"PMC_39401571","title":"Editing Approaches to Treat Alpha-1 Antitrypsin Deficiency.","date":"2024","source":"Chest","url":"https://pubmed.ncbi.nlm.nih.gov/39401571","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35868681","id":"PMC_35868681","title":"Alpha-1 Antitrypsin Deficiency Liver Disease.","date":"2022","source":"Clinics in liver disease","url":"https://pubmed.ncbi.nlm.nih.gov/35868681","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28107454","id":"PMC_28107454","title":"Identification of Novel Short C-Terminal Transcripts of Human SERPINA1 Gene.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28107454","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14692877","id":"PMC_14692877","title":"A new ephrin-A1 isoform (ephrin-A1b) with altered receptor binding properties abrogates the cleavage of ephrin-A1a.","date":"2004","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/14692877","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2268073","id":"PMC_2268073","title":"Polymorphism of pig serum alpha-protease inhibitor-3 (PI3) and assignment of the locus to the Pi1, Po1A, Po1B, Pi2, Igh linkage group.","date":"1990","source":"Animal genetics","url":"https://pubmed.ncbi.nlm.nih.gov/2268073","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8396299","id":"PMC_8396299","title":"Alpha 1-antitrypsin deficiency: an overview.","date":"1993","source":"Acta clinica Belgica","url":"https://pubmed.ncbi.nlm.nih.gov/8396299","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10962087","id":"PMC_10962087","title":"The citrate ion increases the conformational stability of alpha(1)-antitrypsin.","date":"2000","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/10962087","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36805759","id":"PMC_36805759","title":"Soybean transporter AAT Rhg1 abundance increases along the nematode migration path and impacts vesiculation and ROS.","date":"2023","source":"Plant physiology","url":"https://pubmed.ncbi.nlm.nih.gov/36805759","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32482783","id":"PMC_32482783","title":"Granularity of SERPINA1 alleles by DNA sequencing in CanCOLD.","date":"2020","source":"The European respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/32482783","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8060517","id":"PMC_8060517","title":"Acetaldehyde inhibits the anti-elastase activity of alpha 1-antitrypsin.","date":"1994","source":"Alcohol (Fayetteville, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/8060517","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39532838","id":"PMC_39532838","title":"Hepatic SerpinA1 improves energy and glucose metabolism through regulation of preadipocyte proliferation and UCP1 expression.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39532838","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2693888","id":"PMC_2693888","title":"Genetic control of human alpha-1-antitrypsin.","date":"1989","source":"Molecular biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/2693888","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35263815","id":"PMC_35263815","title":"Thrombotic risk determined by rare and common SERPINA1 variants in a population-based cohort study.","date":"2022","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/35263815","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32439252","id":"PMC_32439252","title":"miR-320c Regulates SERPINA1 Expression and Is Induced in Patients With Pulmonary Disease.","date":"2020","source":"Archivos de bronconeumologia","url":"https://pubmed.ncbi.nlm.nih.gov/32439252","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39427920","id":"PMC_39427920","title":"SERPINA1 promotes the invasion, metastasis, and proliferation of pancreatic ductal adenocarcinoma via the PI3K/Akt/NF-κB pathway.","date":"2024","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/39427920","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30929319","id":"PMC_30929319","title":"Beyond the lungs: Alpha-1 antitrypsin's potential role in human gestation.","date":"2019","source":"Advances in clinical and experimental medicine : official organ Wroclaw Medical University","url":"https://pubmed.ncbi.nlm.nih.gov/30929319","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31892136","id":"PMC_31892136","title":"Haplotype in SERPINA1 (AAT) Is Associated with Reduced Risk for COPD in a Mexican Mestizo Population.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31892136","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6973046","id":"PMC_6973046","title":"Inactivation of urinary kallikrein by alpha 1-antitrypsin.","date":"1981","source":"Klinische Wochenschrift","url":"https://pubmed.ncbi.nlm.nih.gov/6973046","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34276045","id":"PMC_34276045","title":"Pulmonary transplantation of alpha-1 antitrypsin (AAT)-transgenic macrophages provides a source of functional human AAT in vivo.","date":"2021","source":"Gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/34276045","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39939782","id":"PMC_39939782","title":"A1AT dysregulation of metabolically stressed hepatocytes by Kupffer cells drives MASH and fibrosis.","date":"2025","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39939782","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2167827","id":"PMC_2167827","title":"Ascitic fluid alpha 1-antitrypsin.","date":"1990","source":"Digestive diseases and sciences","url":"https://pubmed.ncbi.nlm.nih.gov/2167827","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30820592","id":"PMC_30820592","title":"Improving engraftment of hepatocyte transplantation using alpha-1 antitrypsin as an immune modulator.","date":"2019","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/30820592","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19827990","id":"PMC_19827990","title":"Alpha-1 antitrypsin (AAT) deficiency - what are the treatment options?","date":"2009","source":"Expert opinion on pharmacotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/19827990","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12754519","id":"PMC_12754519","title":"Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry.","date":"2003","source":"Nature biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/12754519","citation_count":1176,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11057674","id":"PMC_11057674","title":"Structure of a serpin-protease complex shows inhibition by deformation.","date":"2000","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/11057674","citation_count":926,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22808956","id":"PMC_22808956","title":"Genetically distinct subsets within ANCA-associated vasculitis.","date":"2012","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22808956","citation_count":726,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"6332197","id":"PMC_6332197","title":"Human alpha 1-proteinase inhibitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function.","date":"1984","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/6332197","citation_count":685,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7566098","id":"PMC_7566098","title":"Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence.","date":"1995","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/7566098","citation_count":660,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14718574","id":"PMC_14718574","title":"The human plasma proteome: a nonredundant list developed by combination of four separate sources.","date":"2004","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/14718574","citation_count":658,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7045697","id":"PMC_7045697","title":"Structure and variation of human alpha 1-antitrypsin.","date":"1982","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/7045697","citation_count":609,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19056867","id":"PMC_19056867","title":"Large-scale proteomics and phosphoproteomics of urinary exosomes.","date":"2008","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/19056867","citation_count":607,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1702714","id":"PMC_1702714","title":"Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors.","date":"1990","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1702714","citation_count":572,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26871637","id":"PMC_26871637","title":"Widespread Expansion of Protein Interaction Capabilities by Alternative Splicing.","date":"2016","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26871637","citation_count":423,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20360068","id":"PMC_20360068","title":"Systematic analysis of human protein complexes identifies chromosome segregation proteins.","date":"2010","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/20360068","citation_count":421,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18264092","id":"PMC_18264092","title":"OS-9 and GRP94 deliver mutant alpha1-antitrypsin to the Hrd1-SEL1L ubiquitin ligase complex for ERAD.","date":"2008","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/18264092","citation_count":419,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16344560","id":"PMC_16344560","title":"Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.","date":"2005","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16344560","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"6604220","id":"PMC_6604220","title":"Mutation of antitrypsin to antithrombin. alpha 1-antitrypsin Pittsburgh (358 Met leads to Arg), a fatal bleeding disorder.","date":"1983","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/6604220","citation_count":402,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"6093867","id":"PMC_6093867","title":"Complete sequence of the cDNA for human alpha 1-antitrypsin and the gene for the S variant.","date":"1984","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/6093867","citation_count":370,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16335952","id":"PMC_16335952","title":"Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.","date":"2005","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/16335952","citation_count":350,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10677536","id":"PMC_10677536","title":"Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency.","date":"2000","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10677536","citation_count":338,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10867014","id":"PMC_10867014","title":"Oxidation of either methionine 351 or methionine 358 in alpha 1-antitrypsin causes loss of anti-neutrophil elastase activity.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10867014","citation_count":259,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21060150","id":"PMC_21060150","title":"α-1 Antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8.","date":"2010","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/21060150","citation_count":235,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8756325","id":"PMC_8756325","title":"Inhibitory conformation of the reactive loop of alpha 1-antitrypsin.","date":"1996","source":"Nature structural biology","url":"https://pubmed.ncbi.nlm.nih.gov/8756325","citation_count":230,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17207965","id":"PMC_17207965","title":"hORFeome v3.1: a resource of human open reading frames representing over 10,000 human genes.","date":"2007","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/17207965","citation_count":222,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19738092","id":"PMC_19738092","title":"Genetic modifiers of liver disease in cystic fibrosis.","date":"2009","source":"JAMA","url":"https://pubmed.ncbi.nlm.nih.gov/19738092","citation_count":213,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12464660","id":"PMC_12464660","title":"Alpha1-antitrypsin polymerization and the serpinopathies: pathobiology and prospects for therapy.","date":"2002","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/12464660","citation_count":212,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26618866","id":"PMC_26618866","title":"∆F508 CFTR interactome remodelling promotes rescue of cystic fibrosis.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26618866","citation_count":209,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47603,"output_tokens":6315,"usd":0.118767},"stage2":{"model":"claude-opus-4-6","input_tokens":9932,"output_tokens":3905,"usd":0.220927},"total_usd":0.753302,"stage1_batch_id":"msgbatch_011rkcQdVV1RaFq9XhcG6df6","stage2_batch_id":"msgbatch_01RzgrJafdF4EWHhj5mNi6dh","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":60384,"output_tokens":10502,"usd":0.169341},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":14289,"output_tokens":3656,"usd":0.244267}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1988,\n      \"finding\": \"Alpha-1-antitrypsin (A1AT) inhibits neutrophil elastase through an active site centered around Met358 within an external stressed loop (reactive center loop) on the molecule's surface. The protein is a globular molecule composed of nine alpha-helices and three beta-pleated sheets. Two critical salt bridges (Glu342-Lys290; Glu263-Lys387) maintain structural integrity; mutations disrupting either cause distinct molecular pathology and reduced serum A1AT levels.\",\n      \"method\": \"Biochemical characterization, protein structural analysis, mutagenesis studies\",\n      \"journal\": \"The American journal of medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — foundational structural/mechanistic characterization, extensively replicated across the field\",\n      \"pmids\": [\"3289385\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"Human neutrophil collagenase (MMP-8) cleaves and inactivates alpha-1-antitrypsin. Purified collagenase cleaved A1AT at almost twice the rate of collagen cleavage; this activity was inhibited by 1,10-phenanthroline and by high concentrations of collagen. Neutrophil gelatinase also cleaved A1AT but more slowly.\",\n      \"method\": \"Preparative SDS/PAGE fractionation of neutrophil supernatants, in vitro cleavage assay with purified collagenase, Western blotting, inhibitor studies\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with purified enzyme and substrate, mechanistic inhibitor controls\",\n      \"pmids\": [\"2173552\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Alveolar epithelial cells (human A549 cell line and rat type-II pneumocytes) synthesize and secrete alpha-1-antitrypsin locally, with a modified glycosylation pattern compared to serum AAT. The secreted AAT retains functional activity, forming a complex with neutrophil elastase.\",\n      \"method\": \"Northern blot for AAT mRNA, immunoassay of secreted protein, elastase-AAT complex formation assay\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple methods (mRNA detection, secretion assay, functional complex formation) in a single study\",\n      \"pmids\": [\"8013628\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Neutrophils store alpha-1-antitrypsin intracellularly and, upon surface stimulation (cytochalasin B + fMLP), rapidly secrete both neutrophil elastase and alpha-1-antitrypsin simultaneously. Some of the secreted A1AT forms inhibitory complexes with NE, indicating an intrinsic regulatory mechanism for damping local NE activity.\",\n      \"method\": \"Immunofluorescence, quantitative flow cytometry, [35S]methionine labeling with anti-A1AT immunoprecipitation, secretion assay with fMLP stimulation\",\n      \"journal\": \"American journal of respiratory and critical care medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods establishing storage and co-secretion mechanism\",\n      \"pmids\": [\"8970377\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"The Z variant of alpha-1-antitrypsin (Glu342Lys) causes the protein to misfold and polymerize, leading to retention within the endoplasmic reticulum of hepatocytes. This ER retention causes hepatotoxic liver disease, while reduced circulating A1AT leads to uninhibited proteolytic lung damage.\",\n      \"method\": \"Cell biology studies of mutant protein folding, ER retention assays, biochemical characterization of polymer formation\",\n      \"journal\": \"Clinics in liver disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — well-replicated mechanism across multiple labs and publications in the corpus\",\n      \"pmids\": [\"11232197\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"A surface hydrophobic cavity in alpha-1-antitrypsin (on strand 2 of beta-sheet A, involving residues Thr-114, Gly-117, and Leu-100) is a key determinant of polymer formation. Thr-114→Phe and Gly-117→Phe mutations raised the melting temperature and retarded polymerization without affecting inhibitory activity, while Leu-100→Phe accelerated polymerization. The Thr-114→Phe mutation also reduced polymer formation and increased secretion of Z-A1AT from a Xenopus oocyte expression system.\",\n      \"method\": \"Site-directed mutagenesis, thermal stability assay, polymerization assay, Xenopus oocyte expression, fluorophore binding to cysteine mutants\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis with multiple functional readouts and cell-based validation\",\n      \"pmids\": [\"12807889\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Serpina1 (mouse ortholog of SERPINA1/A1AT) is a potent inhibitor of hematopoietic stem and progenitor cell (HSC/HPC) mobilization induced by IL-8 and G-CSF. Exogenous Serpina1 administration almost completely inhibited mobilization; heat-inactivated Serpina1 had no effect, indicating the mechanism depends on its serine protease inhibitor activity. Low-dose irradiation induces Serpina1 in bone marrow, which inhibits mobilization.\",\n      \"method\": \"In vivo administration of purified Serpina1 before IL-8 injection in mice, antibody neutralization of Serpina1 in BM extracts, mRNA and protein quantification in BM after irradiation\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo functional assay with heat-inactivation control and antibody neutralization establishing mechanism\",\n      \"pmids\": [\"16432201\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Alpha-1-antitrypsin is internalized by lung endothelial cells via clathrin-mediated endocytosis, not caveolae-mediated endocytosis. A1AT associates with clathrin heavy chains but not caveolin-1 at the plasma membrane. This intracellular uptake is required for A1AT's anti-apoptotic function in endothelial cells. Cigarette smoke exposure inhibits A1AT uptake and alters clathrin heavy chain distribution.\",\n      \"method\": \"Specific inhibition of clathrin vs. caveolae-mediated endocytosis, co-immunoprecipitation with clathrin heavy chains vs. caveolin-1, time-dependent/dose-dependent uptake assays, in vitro and in vivo (mouse) cigarette smoke exposure\",\n      \"journal\": \"FASEB journal : official publication of the Federation of American Societies for Experimental Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods linking specific endocytic mechanism to functional anti-apoptotic outcome\",\n      \"pmids\": [\"19423638\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Serpina1 protein in bone marrow extracellular fluid is predominantly produced by osteoblasts (not hematopoietic cells), positioning osteoblasts as a source of the HSC niche regulator Serpina1.\",\n      \"method\": \"Isolation of osteoblast and hematopoietic BM fractions, qRT-PCR for Serpina1 mRNA, Western blot of conditioned supernatants, immunohistochemistry of BM sections\",\n      \"journal\": \"Experimental hematology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple methods in single study localizing Serpina1 production to osteoblasts with functional context\",\n      \"pmids\": [\"19375654\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"A1AT is actively transcytosed across lung endothelial cells. Taken up basolaterally by endothelial cells, A1AT is secreted both apically and basolaterally and transferred to adjacent lung epithelial cells. A1AT co-localizes with Golgi in endothelium; inhibition of classical secretory pathway increases intracellular retention but promotes non-classical secretion via microparticle release. Polymerized A1AT and cigarette smoke extract impair transcytosis.\",\n      \"method\": \"Transwell co-culture system with polarized endothelial and epithelial cells, time-lapse confocal microscopy, two-photon intravital microscopy in mice, tunicamycin inhibition of Golgi secretion\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods including in vivo two-photon microscopy establishing transcytosis mechanism\",\n      \"pmids\": [\"24743137\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Scavenger receptor class B type I (SR-BI) mediates endocytosis of A1AT by pulmonary endothelial cells. SR-BI immunoprecipitation identified binding to A1AT at the plasma membrane. Knockdown of SCARB1, HDL/LDL pretreatment, or neutralizing SR-BI antibodies reduced A1AT uptake by 30–50%. Scarb1 null mice showed decreased lung A1AT content and reduced anti-inflammatory effects of A1AT supplementation. A1AT uptake also occurs via clathrin-coated vesicles and caveolae as confirmed by transmission electron microscopy with colloidal gold-labeled A1AT.\",\n      \"method\": \"SR-BI immunoprecipitation, SCARB1 knockdown, neutralizing antibody, SR-BI ligand competition, transmission electron microscopy with colloidal gold labeling, Scarb1 knockout mice\",\n      \"journal\": \"American journal of physiology. Lung cellular and molecular physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — reconstitution-level evidence with multiple orthogonal methods and in vivo knockout validation\",\n      \"pmids\": [\"26092999\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"NQO1 (NAD(P)H:quinone oxidoreductase 1) acts as an RNA-binding protein that binds the 3'UTR and coding region of SERPINA1 mRNA, enhancing its translation without affecting mRNA levels. NQO1 silencing decreased polysome loading on SERPINA1 mRNA and reduced A1AT protein abundance. NQO1-KO mice had reduced hepatic and serum A1AT and increased neutrophil elastase activity.\",\n      \"method\": \"Ribonucleoprotein immunoprecipitation (RIP) with microarray, biotin pulldown of NQO1 with SERPINA1 mRNA segments, polysome profiling, luciferase reporter assay with SERPINA1 3'UTR, NQO1-KO mice\",\n      \"journal\": \"Free radical biology & medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (RIP, biotin pulldown, polysome profiling, reporter assay, KO mice) in single study\",\n      \"pmids\": [\"27515817\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"The SERPINA1 V213A coding variant (M1 A213 vs. Val-213) modulates A1AT interaction with neutrophil elastase (NE) in lipoprotein-containing plasma. The M1(A213) variant exhibits an almost 2-fold lower dissociation constant with NE in lipoprotein-containing (but not lipid-free) plasma. Hydrogen/deuterium exchange mass spectrometry revealed the Val-213 variant has reduced global flexibility. The gate region around position 213 modulates the interplay between AAT, NE, and lipoprotein particles.\",\n      \"method\": \"Quantitative microscale thermophoresis (binding assay), hydrogen/deuterium exchange mass spectrometry for structural flexibility comparison\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biophysical binding assay plus structural H/D exchange MS in a single rigorous study\",\n      \"pmids\": [\"28265093\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"The pathological Trento variant of alpha-1-antitrypsin (E75V) is secreted efficiently from cells (unlike Z-AAT) but shows compromised conformational stability and forms oligomeric polymers with distinct electrophoretic and immunorecognition profiles compared to Z and S polymers. Structural analyses indicate the mutation disrupts a conserved stabilizing interaction between helix C and the posthelix I loop as the basis for polymerization.\",\n      \"method\": \"Cellular expression assays, polyacrylamide gel electrophoresis, ELISA with conformational monoclonal antibodies, structural analysis, epitope localization between helices E and F\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple methods establishing distinct polymer mechanism, single lab study\",\n      \"pmids\": [\"28504839\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"A1AT promotes chondrogenic differentiation through activation of PKA-dependent CREB signaling and inhibition of Wnt/β-catenin pathways in human chondrocytes. In vivo, A1AT reverses joint inflammation, nociception, and cartilage degradation in KBxN serum and neutrophil elastase models of arthritis, and promotes transcription of col2a1, acan, and sox9 while downregulating mmp13 and adamts5.\",\n      \"method\": \"SERPINA1 transfection and rAAT protein treatment of human chondrocytes, in vitro signaling pathway analysis (PKA/CREB and Wnt/β-catenin), intra-articular and systemic AAT administration in mouse arthritis models, ex vivo gene expression analysis\",\n      \"journal\": \"FASEB journal : official publication of the Federation of American Societies for Experimental Biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro pathway dissection with in vivo disease model, single lab\",\n      \"pmids\": [\"33788977\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The 5'-UTR of the SERPINA1 NM_000295.4 transcript folds into a well-defined multi-helix structural domain that promotes translation by maintaining accessibility at the translation initiation site. Systematic destabilization of the 5'-UTR structure revealed that mutations disrupting the anchoring helix create non-native structures with a stable helix near the AUG that decreases translation, establishing that global 5'-UTR folding (not local structure per se) regulates SERPINA1 mRNA translation.\",\n      \"method\": \"SHAPE (selective 2'-hydroxyl acylation analyzed by primer extension) quantification of RNA structure, systematic mutagenesis of 5'-UTR, cap-dependent translation reporter assays\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic mutagenesis combined with quantitative RNA structure probing and translation assays\",\n      \"pmids\": [\"36107773\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SERPINA1 is expressed in villous trophoblasts of the placenta and localizes to decidual fibrinoid deposits. siRNA knockdown of SERPINA1 in trophoblast-derived HTR8/SVneo cells markedly affects the actin cytoskeleton pathway, Slit-Robo signaling, and extracellular matrix organization, suggesting A1AT regulates proteolysis-dependent processes critical for maintaining pregnancy.\",\n      \"method\": \"Placental proteomics, whole exome sequencing, immunoelectron microscopy for localization, siRNA knockdown with pathway analysis in trophoblast cells\",\n      \"journal\": \"BMC medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — siRNA functional knockdown with pathway readout and localization by immunoelectron microscopy, single study\",\n      \"pmids\": [\"35477570\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SerpinA1 (A1AT) forms a complex with Eph receptor B2 (EphB2) and regulates its downstream signaling in adipocytes, leading to proliferation of white and brown preadipocytes and increased UCP1 expression in mature adipocytes. Liver-specific SerpinA1 transgenic mice show increased adipose tissue browning, increased energy expenditure, and improved glucose tolerance; SerpinA1 knockout mice display impaired adipocyte mitochondrial function, obesity, and systemic insulin resistance.\",\n      \"method\": \"Co-immunoprecipitation of SerpinA1–EphB2 complex, liver-specific transgenic and knockout mouse models, measurement of UCP1 expression, preadipocyte proliferation assay, metabolic phenotyping\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP identifying binding partner, complementary transgenic and KO mouse models with defined metabolic phenotypes\",\n      \"pmids\": [\"39532838\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"IL-1β from Kupffer cells suppresses A1AT expression in hepatocytes via transcriptional inhibition mediated by HNF4α. In A1AT-deficient (quintuple Serpina1a-e knockout) mice, loss of A1AT increases activity of proteinase 3 (PR3), a serine protease from monocyte-derived Kupffer cells. PR3 cleaves IL-32γ, converting it from an anti-inflammatory/antifibrogenic cytokine into a Kupffer cell activator and abolishing its antifibrotic effects, thereby driving MASH and liver fibrosis progression.\",\n      \"method\": \"Quintuple Serpina1a-e knockout mice, A1AT restoration and PR3 inhibition experiments, cytokine array identifying IL-32γ as PR3 substrate, IL-32γ V104A cleavage-resistant mutation, in vivo IL-32γ overexpression, PR3 activity assays, HNF4α transcription factor analysis\",\n      \"journal\": \"Experimental & molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — genetic KO with enzyme activity assay, substrate identification, cleavage-resistant mutant validation, and mechanistic pathway dissection\",\n      \"pmids\": [\"39939782\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Acetaldehyde (major metabolite of ethanol) at 0.3–1.2 M concentrations inhibits the anti-elastase activity of alpha-1-antitrypsin in vitro, while equivalent concentrations of ethanol have no effect. This provides a biochemical mechanism by which alcohol metabolism could impair A1AT's protective antiprotease function.\",\n      \"method\": \"In vitro elastase activity assay in presence of A1AT and acetaldehyde/ethanol at varying concentrations\",\n      \"journal\": \"Alcohol (Fayetteville, N.Y.)\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single in vitro assay, concentrations above physiological range, single lab\",\n      \"pmids\": [\"8060517\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Sodium citrate stabilizes the native active conformation of alpha-1-antitrypsin, increasing resistance to guanidine-HCl unfolding (midpoint increased by 1.8 M) and heat inactivation (~30-fold), while A1AT remains fully active forming a 1:1 complex with chymotrypsin. Citrate increases insertion rate of exogenous reactive-center loop peptide, suggesting structural effects on the A beta-sheet region.\",\n      \"method\": \"Guanidine HCl denaturation, heat inactivation assay, chymotrypsin inhibition assay (stoichiometry of inhibition), fluorescence and circular dichroism spectroscopy, exogenous reactive-center loop peptide insertion assay\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — multiple biophysical methods characterizing conformational effects, single lab\",\n      \"pmids\": [\"10962087\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CEBPB binds the SERPINA1 gene promoter and drives SERPINA1 transcription in colorectal cancer cells. SERPINA1 in turn promotes proliferation and migration by activating STAT3 signaling. Knockdown of SERPINA1 attenuates STAT3 activation, and the CEBPB–SERPINA1–STAT3 axis drives CRC liver metastasis.\",\n      \"method\": \"ChIP and luciferase reporter assays for CEBPB binding to SERPINA1 promoter, SERPINA1 knockdown/overexpression, STAT3 pathway analysis, in vitro migration/invasion assays, in vivo liver metastasis mouse model\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus reporter assay plus functional knockdown with pathway readout, single lab\",\n      \"pmids\": [\"38710698\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"miR-320c binds the 3'UTR region of SERPINA1 mRNA and inhibits its expression. Overexpression of miR-320 family members in HepG2 hepatic cells leads to inhibition of SERPINA1 mRNA and protein levels; this regulation is post-transcriptional.\",\n      \"method\": \"miR-320 overexpression in HepG2 cells with SERPINA1 mRNA/protein measurement, predicted binding site in SERPINA1 3'UTR\",\n      \"journal\": \"Archivos de bronconeumologia\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single overexpression experiment without direct 3'UTR luciferase validation, single lab\",\n      \"pmids\": [\"35698951\", \"32439252\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SERPINA1 encodes alpha-1-antitrypsin (A1AT), a serine protease inhibitor that forms a suicide-substrate complex with neutrophil elastase via its reactive center loop Met358, inhibiting protease-mediated lung destruction; the common Z variant (E342K) disrupts a critical salt bridge causing misfolding and ER retention with polymerization in hepatocytes, producing liver disease and loss-of-function lung disease; A1AT is secreted by hepatocytes, alveolar epithelial cells, and neutrophils, trafficked across lung endothelium via clathrin/SR-BI-mediated endocytosis and transcytosis to reach alveolar epithelial cells; it inhibits HSC mobilization by blocking serine protease activity in the bone marrow niche (produced by osteoblasts); regulates metabolism as a hepatokine by forming a complex with EphB2 receptor to promote preadipocyte proliferation and UCP1-driven thermogenesis; and in the liver suppresses proteinase 3 (PR3) activity downstream of HNF4α-mediated transcriptional control, preventing PR3-mediated cleavage of IL-32γ and thus protecting against MASH and fibrosis.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll classify each paper and extract discoveries only from KEEP papers.\n\n**Key exclusions:**\n- Papers [5] (Photosystem I phylloquinone - plant protein), [6] (HMGA1a/STAT3 - different gene), [15] (HMGA1a/Ras/ERK - different gene), [26] (HMGA1a phosphorylation - different gene), [28] (Aspergillus aat/penDE - fungal penicillin biosynthesis gene), [36] (Pi1 scorpion toxin - different gene), [37] (pig PI1/PO1A etc - different genes), [66] (HMGA1a PTMs - different gene), [68] (Gly m 6 acidic polypeptides A1a - soybean allergen), [81] (ephrin-A1b - different gene), [82] (pig PI3 - different gene), [85] (soybean AAT Rhg1 - plant amino acid transporter)\n\nFrom the curated list: [1-4] (general genomics/proteomics, not mechanistic for SERPINA1), [3,4,7,9,11,13,16,17] (interactomes/genomics projects - not SERPINA1-specific mechanism), [10,11,13] same, [19] (alternative promoters - general), [27] (hORFeome - general)\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1984,\n      \"finding\": \"Crystal structure of alpha-1-antitrypsin (cleaved form) determined at 3 Å resolution, revealing the polypeptide arranged into three beta-sheets (A, B, C) and eight alpha-helices. The structure showed that Met358 and Ser359 chain ends are on opposite poles of the molecule, indicating a major conformational rearrangement upon cleavage of the reactive center loop. Glu342, mutated to Lys in the Z-variant, was identified in a strategic position for this rearrangement.\",\n      \"method\": \"X-ray crystallography (isomorphous replacement, cyclic averaging of two crystal forms, crystallographic refinement to R~0.25)\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure at 3 Å, two independent crystal forms, foundational structural paper with 685 citations\",\n      \"pmids\": [\"6332197\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1982,\n      \"finding\": \"Primary sequence analysis of alpha-1-antitrypsin established its role as a tissue scavenger of leukocyte elastase and showed that two abnormal variants (S and Z) common in Europeans cause deficiency predisposing to emphysema. Cigarette smoking was shown to greatly accelerate the degenerative process by inactivating the reactive center.\",\n      \"method\": \"Protein sequence determination and variant analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct protein sequencing with functional interpretation, 609 citations, foundational paper\",\n      \"pmids\": [\"7045697\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1983,\n      \"finding\": \"Mutation of the active-site Met358 to Arg in the Pittsburgh variant converted alpha-1-antitrypsin from an elastase inhibitor to a thrombin inhibitor (antithrombin activity), establishing Met358 as the reactive center that acts as 'bait' for neutrophil elastase, analogous to Arg393 in antithrombin III acting as bait for thrombin. This confirmed that reactive center identity determines protease specificity.\",\n      \"method\": \"Characterization of a naturally occurring Met358Arg mutation in a patient with fatal bleeding disorder; plasma protein analysis\",\n      \"journal\": \"The New England journal of medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — active-site mutation with defined functional switch, replicated across serpin family, 402 citations\",\n      \"pmids\": [\"6604220\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1984,\n      \"finding\": \"Complete cDNA and gene sequence of alpha-1-antitrypsin determined, revealing a 24-amino acid signal peptide and 394-amino acid mature protein. The S-variant gene was sequenced, identifying a single base substitution (A→T) causing Glu264→Val substitution. The gene structure includes four coding exons and a 5.3 kb intron in the 5' noncoding region.\",\n      \"method\": \"cDNA cloning and sequencing; gene subcloning and sequencing\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct sequencing establishing gene structure and variant molecular basis, 370 citations\",\n      \"pmids\": [\"6093867\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"Comprehensive molecular characterization of A1AT established: (1) the protein is a 52-kDa, 394-amino acid globular molecule with nine alpha-helices and three beta-pleated sheets; (2) the active site is centered around Met358 in an external stressed reactive center loop; (3) two critical salt bridges (Glu342-Lys290; Glu263-Lys387) exist within the molecule, and disruption of either causes distinct molecular pathology reducing serum A1AT levels; (4) over 75 variants exist categorized as normal, deficient, dysfunctional, or absent.\",\n      \"method\": \"Protein structural analysis, molecular biology, restriction fragment analysis, oligonucleotide probing, direct gene sequencing\",\n      \"journal\": \"The American journal of medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — comprehensive structural and molecular characterization, multiple orthogonal methods, 428 citations\",\n      \"pmids\": [\"3289385\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Crystal structure of alpha-1-antitrypsin at 2.9 Å resolution showed the reactive site loop in a stable canonical beta-pleated strand conformation matching that found in all other serine proteinase inhibitor families (Kunitz, Kazal), without loop insertion into the body of the molecule. This favors a two-stage mechanism of inhibition and provides a structural basis for serpin polymerization in disease and for association with beta-amyloid.\",\n      \"method\": \"X-ray crystallography at 2.9 Å resolution\",\n      \"journal\": \"Nature structural biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution crystal structure with functional interpretation, 230 citations\",\n      \"pmids\": [\"8756325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Crystal structure of a serpin-protease complex revealed the complete mechanism of inhibition: the conformational change is initiated by reaction of the protease's active serine with the serpin reactive center, cleaving it. The cleaved reactive center loop then translocates 71 Å to the opposite pole of the serpin, dragging the tethered protease with it. This causes 37% loss of structure in the protease through distortion of its active site (plucking of the serine from its catalytic triad), preventing release of the protease from the complex and allowing its proteolytic destruction.\",\n      \"method\": \"X-ray crystallography of serpin-protease complex\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure of the inhibitory complex directly revealing mechanism, foundational serpin biology paper with 926 citations\",\n      \"pmids\": [\"11057674\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Oxidation of either Met351 or Met358 in alpha-1-antitrypsin causes loss of anti-neutrophil elastase activity. Both methionines are equally susceptible to hydrogen peroxide oxidation (confirmed by mass spectrometry). Single mutants M351V and M358V showed partial resistance to oxidative inactivation, while the double mutant M351V/M358V was markedly resistant, establishing that oxidation of either residue can inactivate A1AT and providing a mechanism for regulation of A1AT activity at sites of inflammation (e.g., by cigarette smoke).\",\n      \"method\": \"Site-directed mutagenesis of recombinant A1AT; hydrogen peroxide treatment; mass spectrometry for oxidation site identification; elastase inhibition assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution with mutagenesis and MS confirmation, multiple orthogonal methods, 259 citations\",\n      \"pmids\": [\"10867014\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Chemical chaperones, particularly 4-phenylbutyric acid (PBA), mediate increased secretion of functionally active mutant Z alpha-1-antitrypsin (alpha1-ATZ) from the ER. Oral administration of PBA to PiZ transgenic mice increased blood levels of human alpha-1-AT to 20-50% of normal levels, demonstrating that pharmacological intervention in ER retention of misfolded Z-A1AT is possible.\",\n      \"method\": \"Cell culture model (secretion assay); in vivo oral administration to PiZ transgenic mice; functional activity assessment\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vitro and in vivo orthogonal evidence, 338 citations\",\n      \"pmids\": [\"10677536\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"Neutrophil collagenase (MMP-8) is capable of cleaving and inactivating alpha-1-antitrypsin. Purified collagenase cleaved A1AT at almost twice the rate at which it cleaved type I collagen. Neutrophil gelatinase also cleaved A1AT but slowly. This was demonstrated by co-fractionation of collagenase and A1AT-cleaving activities by SDS-PAGE and confirmed with purified collagenase preparations, establishing metalloproteinase-mediated inactivation of the primary neutrophil elastase inhibitor.\",\n      \"method\": \"Preparative SDS-PAGE fractionation of neutrophil supernatant; incubation with purified substrates; Western blot; purified collagenase activity assay; inhibitor studies with 1,10-phenanthroline\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — purified enzyme reconstitution with substrate, inhibitor validation, multiple approaches, 92 citations\",\n      \"pmids\": [\"2173552\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"Prostate-specific antigen (PSA) forms stable SDS-stable complexes with alpha-1-antichymotrypsin (but also interacts with alpha-2-macroglobulin) when added to normal blood plasma in vitro. PSA cleaves the inhibitor at a position identical to that reported for chymotrypsin-alpha-1-antichymotrypsin reaction, demonstrating that A1AT-family serpins can form covalent inhibitory complexes with serine proteases via standard serpin mechanism.\",\n      \"method\": \"In vitro complex formation with purified proteins; SDS-PAGE; plasma incubation experiments\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro reconstitution with purified proteins; primarily about PSA/alpha-1-antichymotrypsin but demonstrates serpin inhibitory mechanism, 572 citations\",\n      \"pmids\": [\"1702714\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Alveolar epithelial cells (human A549 cell line and rat type-II pneumocytes) synthesize and secrete alpha-1-antitrypsin with modified glycosylation compared to serum AAT. The secreted A1AT retains the ability to form complexes with neutrophil elastase, establishing alveolar epithelial cells as a local source of A1AT for antiprotease defense within the lung.\",\n      \"method\": \"Northern blot for mRNA; immunoreactive AAT measurement by ELISA; complex formation assay with neutrophil elastase\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (mRNA, secretion, functional assay) in two cell types\",\n      \"pmids\": [\"8013628\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Neutrophils store alpha-1-antitrypsin intracellularly and release it concordantly with neutrophil elastase (NE) upon surface stimulation. Flow cytometry showed decreased intracellular A1AT after stimulation with cytochalasin B/fMLP. Radiolabeling and immunoprecipitation demonstrated increased secretion of A1AT from stimulated neutrophils, with some secreted A1AT forming complexes with NE. This establishes an intrinsic mechanism by which neutrophils dampen the local effects of their own most powerful proteolytic enzyme.\",\n      \"method\": \"Immunofluorescence; quantitative flow cytometry; [35S]methionine labeling and immunoprecipitation; surface stimulation with cytochalasin B/fMLP\",\n      \"journal\": \"American journal of respiratory and critical care medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods demonstrating storage and release with functional complex formation\",\n      \"pmids\": [\"8970377\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Alpha-1-antitrypsin deficiency and the serpinopathies are characterized by pathological polymerization of mutant A1AT (Z variant, Glu342Lys) within the ER of hepatocytes, forming ordered polymers that cause liver disease while reduced circulating A1AT causes lung disease. The Z mutation disrupts the critical Glu342-Lys290 salt bridge, destabilizing the molecule and promoting polymer formation via aberrant beta-sheet interactions.\",\n      \"method\": \"Review synthesizing structural, cell biological, and molecular genetic data on serpin polymerization\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — synthesis of multiple experimental datasets on polymerization mechanism, 212 citations\",\n      \"pmids\": [\"12464660\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"A hydrophobic surface cavity in alpha-1-antitrypsin on strand 2 of beta-sheet A (around residues Thr114, Gly117, Leu100) was identified as a target for preventing polymer formation. Mutations Thr114→Phe and Gly117→Phe significantly raised the melting temperature and retarded polymer formation without affecting inhibitory activity, while Leu100→Phe accelerated polymerization. Thr114→Phe reduced polymer formation and increased secretion of Z-A1AT from Xenopus oocytes. Cysteine mutants in the cavity could bind fluorophores, confirming accessibility.\",\n      \"method\": \"Site-directed mutagenesis; thermal stability assay; polymerization assay; Xenopus oocyte expression system; fluorophore binding to cysteine mutants\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis with multiple functional readouts (stability, polymerization, secretion, ligand binding) in multiple systems\",\n      \"pmids\": [\"12807889\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Serpina1 (alpha-1-antitrypsin) acts as a potent inhibitor of IL-8-induced hematopoietic stem cell (HSC) and hematopoietic progenitor cell (HPC) mobilization. After low-dose total-body irradiation (0.5 Gy), Serpina1 mRNA and protein increased in bone marrow extracellular extracts. Antibody neutralization of Serpina1 reversed inhibitory activity. Exogenous Serpina1 administration almost completely inhibited HSC/HPC mobilization, while heat-inactivated Serpina1 had no effect, demonstrating that elastase-inhibitory activity is required for this function.\",\n      \"method\": \"In vivo mouse model; bone marrow extract biochemistry; anti-Serpina1 antibody neutralization; exogenous protein administration; heat inactivation control\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple in vivo and ex vivo approaches with antibody neutralization and heat-inactivation controls, 54 citations\",\n      \"pmids\": [\"16432201\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"OS-9 (an ER-resident lectin) and GRP94 (ER chaperone) deliver mutant alpha-1-antitrypsin (Z variant) to the Hrd1-SEL1L ubiquitin ligase complex for ER-associated degradation (ERAD). OS-9 binds ERAD substrates and, through the SEL1L adaptor, connects to Hrd1. GRP94, together with Hrd1 and SEL1L, is required for degradation of mutant alpha-1-antitrypsin, placing Z-A1AT degradation in a defined ERAD pathway.\",\n      \"method\": \"Co-immunoprecipitation; RNAi knockdown; protein degradation assays in mammalian cells\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP with functional knockdown validation, 419 citations\",\n      \"pmids\": [\"18264092\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Alpha-1-antitrypsin is internalized by primary rat lung microvascular endothelial cells via clathrin-mediated (not caveolae-mediated) endocytosis. A1AT associates with clathrin heavy chains but not caveolin-1 at the plasma membrane. Inhibition of clathrin-mediated endocytosis profoundly decreased A1AT internalization and reversed its antiapoptotic action. Cigarette smoke exposure significantly inhibited A1AT uptake in endothelial cells and in mouse lung in vivo, and altered intracellular distribution of clathrin heavy chains.\",\n      \"method\": \"Specific pharmacological inhibition of endocytic pathways; co-immunoprecipitation with clathrin heavy chain and caveolin-1; in vitro and in vivo (mouse) cigarette smoke exposure; apoptosis assay\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — pathway-specific inhibition with functional readout, biochemical binding, in vitro and in vivo validation, 48 citations\",\n      \"pmids\": [\"19423638\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Serpina1 protein in bone marrow extracellular fluid is predominantly produced by osteoblasts (OB), not hematopoietic cells. Quantitative RT-PCR showed high Serpina1 mRNA in OB; Western blot confirmed Serpina1 secretion by OB but not by hematopoietic cells; immunohistochemistry localized Serpina1 protein to OB lining the bone. This establishes that Serpina1 is synthesized in the osteoblastic stem cell niche and may regulate HSC maintenance.\",\n      \"method\": \"Quantitative RT-PCR; Western blot; immunohistochemistry on bone marrow sections\",\n      \"journal\": \"Experimental hematology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (mRNA, protein, localization) establishing cellular source\",\n      \"pmids\": [\"19375654\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Glycosylated AAT directly binds IL-8 (a CXCR1 ligand), and AAT-IL-8 complex formation prevents IL-8 interaction with CXCR1, thereby inhibiting CXCR1-mediated neutrophil chemotaxis. Additionally, AAT controls soluble immune complex (sIC)-induced neutrophil chemotaxis by inhibiting ADAM-17 enzymatic activity, thereby maintaining membrane expression of the GPI-anchored Fc receptor FcγRIIIb. These two distinct pathways of AAT-mediated neutrophil chemotaxis regulation were confirmed in AAT-deficient patients and restored by augmentation therapy.\",\n      \"method\": \"Binding assays (AAT-IL-8 complex formation); CXCR1 interaction studies; ADAM-17 enzymatic inhibition assay; FcγRIIIb membrane expression by flow cytometry; human patient samples before/after augmentation therapy\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct binding assay, enzymatic inhibition, human patient validation; multiple orthogonal methods; 235 citations\",\n      \"pmids\": [\"21060150\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"A1AT is actively transported (transcytosed) across lung endothelial cells to the alveolar epithelium. Purified A1AT was taken up by confluent endothelial monolayers and secreted both apically and basolaterally. A1AT co-localized with Golgi in endothelium; inhibition of classical secretory pathway increased intracellular retention but promoted non-classical secretion via microparticle release. Polymerized A1AT or cigarette smoke extract impaired transcytosis. In vivo evidence was obtained by two-photon intravital microscopy in mice.\",\n      \"method\": \"Polarized transwell co-culture; confocal time-lapse microscopy; Golgi inhibition (tunicamycin); two-photon intravital microscopy in mice; microparticle analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vitro and in vivo orthogonal approaches with mechanistic pathway manipulation, 42 citations\",\n      \"pmids\": [\"24743137\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Scavenger receptor B type I (SR-BI) mediates A1AT endocytosis by pulmonary endothelial cells. SR-BI immunoprecipitation identified binding to A1AT at the plasma membrane. Knockdown of SCARB1 expression, pretreatment with SR-B ligands (HDL or LDL), or neutralizing SR-BI antibodies reduced A1AT uptake by 30-50%. Scarb1 null mice exhibited decreased lung A1AT content following systemic A1AT administration and reduced anti-inflammatory effects of A1AT during cigarette smoke exposure. Transmission electron microscopy confirmed A1AT endocytosis in both clathrin-coated vesicles and caveolae.\",\n      \"method\": \"SR-BI immunoprecipitation; siRNA knockdown; competitive ligand pretreatment; neutralizing antibodies; Scarb1 knockout mice; transmission electron microscopy with colloidal gold-labeled A1AT\",\n      \"journal\": \"American journal of physiology. Lung cellular and molecular physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — receptor identification by Co-IP, knockdown, KO mice, and EM, multiple orthogonal methods, 18 citations\",\n      \"pmids\": [\"26092999\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"NQO1 (NAD(P)H:quinone oxidoreductase 1) acts as an RNA-binding protein that binds the 3'UTR and coding region of SERPINA1 mRNA and enhances its translation without affecting mRNA levels. NQO1 silencing decreased polysome size on SERPINA1 mRNA and lowered A1AT protein abundance. Luciferase reporter analysis confirmed regulation through the SERPINA1 3'UTR. NQO1-knockout mice had reduced hepatic and serum A1AT levels and increased neutrophil elastase activity.\",\n      \"method\": \"RNP immunoprecipitation (RIP) and microarray; biotin pulldown of SERPINA1 mRNA regions; polysome profiling; luciferase reporter assay; NQO1 siRNA knockdown; NQO1-KO mice\",\n      \"journal\": \"Free radical biology & medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (RIP, pulldown, polysome profiling, reporter, KO mice), in vitro and in vivo\",\n      \"pmids\": [\"27515817\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"The coding variant V213A (rs568223361) in SERPINA1 modulates AAT interaction with neutrophil elastase (NE) in lipoprotein-containing plasma. Quantitative microscale thermophoresis showed M1(A213) AAT has an almost twofold lower dissociation constant with NE in lipoprotein-containing (but not lipid-free) plasma. Hydrogen/deuterium exchange mass spectrometry revealed significant differences in global flexibility between V213 and A213 variants. The Val-213 variant shows stronger lipoprotein interaction and reduced global flexibility, improving local availability and reducing proteolytic inactivation by other proteases in atherosclerotic plaques.\",\n      \"method\": \"Quantitative microscale thermophoresis; hydrogen/deuterium exchange coupled mass spectrometry\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — two orthogonal biophysical methods (MST binding kinetics, H/D exchange MS) with mechanistic interpretation\",\n      \"pmids\": [\"28265093\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"The Trento variant of AAT (E75V) shows non-classical polymerization behavior distinct from Z (E342K) and S (E264V) variants. Trento AAT is efficiently secreted in cellular models but has compromised conformational stability. PAGE and ELISA revealed oligomeric species with different electrophoretic and immunorecognition profiles, including reduced recognition by conformational monoclonal antibodies 2C1 and 4B12. Structural analysis localized the 2C1 epitope between helices E and F and indicated that E75V disrupts a stabilizing interaction between helix C and the post-helix I loop, causing polymer formation through a different structural pathway.\",\n      \"method\": \"Cell expression models; PAGE; conformational antibody ELISA; epitope mapping; structural analysis\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — conformational antibody mapping, structural analysis, multiple biochemical assays in cell models\",\n      \"pmids\": [\"28504839\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Acetaldehyde (at 0.3–1.2 M concentrations) inhibits the anti-elastase activity of alpha-1-antitrypsin in biochemical assays, while equivalent concentrations of ethanol have no effect on elastase activity or A1AT function. This provides a biochemical mechanism by which alcohol metabolism may compound A1AT deficiency.\",\n      \"method\": \"In vitro elastase inhibition assay with purified A1AT and acetaldehyde/ethanol\",\n      \"journal\": \"Alcohol (Fayetteville, N.Y.)\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single in vitro biochemical assay, supra-physiological acetaldehyde concentrations\",\n      \"pmids\": [\"8060517\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Sodium citrate at low concentrations increases the conformational stability of alpha-1-antitrypsin without affecting inhibitory activity, as demonstrated by a 1.8 M increase in midpoint of guanidine hydrochloride-induced unfolding and ~30-fold decrease in heat inactivation rate at 0.5 M citrate. Citrate also increased the insertion rate of exogenous reactive-center loop peptide into the A beta-sheet, indicating structural changes in the sheet region despite unaltered tertiary structure by fluorescence and CD spectroscopy.\",\n      \"method\": \"Guanidine hydrochloride denaturation; heat inactivation kinetics; fluorescence spectroscopy; circular dichroism; exogenous peptide insertion assay; chymotrypsin inhibition assay\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — multiple biophysical assays on purified protein revealing conformational mechanism\",\n      \"pmids\": [\"10962087\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Carbamylated alpha-1-antitrypsin (Ca-A1AT) is an antigenic target of anti-carbamylated protein (anti-CarP) antibodies in rheumatoid arthritis patients. A1AT contains multiple surface lysines that are readily carbamylated. Mass spectrometry identified carbamylated A1AT in synovial fluid of an RA patient. This establishes A1AT as a post-translationally modified autoantigen in RA via carbamylation.\",\n      \"method\": \"Ion exchange chromatography fractionation; mass spectrometry for carbamylated protein identification; ELISA; synovial fluid mass spectrometry\",\n      \"journal\": \"Journal of autoimmunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — MS identification of modification site, patient sample confirmation, ELISA validation\",\n      \"pmids\": [\"28291659\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The 5'-UTR of SERPINA1 NM_000295.4 transcript folds into a well-defined multi-helix structural domain that optimizes translation by promoting accessibility at the translation initiation site. Systematic destabilization of mRNA structure across the 5'-UTR showed that most structure-destabilizing mutations had no effect on or decreased translation despite disrupting local structure, because they retained global 5'-UTR structure. Mutations disrupting the helix anchoring the 5'-UTR domain created non-native structures forming a stable helix near the translation initiation site that decreases translation.\",\n      \"method\": \"SHAPE quantification of RNA structure; systematic mutagenesis across 5'-UTR; cap-dependent translation reporter assays; RNA structure analysis\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic mutagenesis combined with SHAPE structure probing and translation reporter assays, multiple orthogonal approaches\",\n      \"pmids\": [\"36107773\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"miR-320c directly inhibits SERPINA1 expression in hepatic HepG2 cells via binding sites in the 3'UTR region of SERPINA1 mRNA. Overexpression of miR-320 family members in HepG2 cells led to inhibition of SERPINA1 expression. LPS treatment of HL60 cells increased miR-320c expression, suggesting inflammation-mediated regulation of A1AT through this miRNA.\",\n      \"method\": \"miRNA overexpression in HepG2 cells; quantitative PCR; LPS stimulation of HL60 cells; correlation with patient samples\",\n      \"journal\": \"Archivos de bronconeumologia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — overexpression experiment in cell line with functional readout, replicated in two publications (PMID 35698951 and 32439252)\",\n      \"pmids\": [\"35698951\", \"32439252\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Hepatic SerpinA1/A1AT functions as a hepatokine that improves energy and glucose metabolism by: (1) inducing proliferation of white and brown preadipocytes; (2) increasing UCP1 expression to promote mitochondrial activation in adipocytes; (3) forming a complex with the Eph receptor B2 (EphB2) and regulating its downstream signaling in adipocytes. Liver-specific SerpinA1 transgenic mice showed increased adipose browning, energy expenditure, and improved glucose tolerance. SerpinA1 knockout mice had decreased adipocyte mitochondrial function, impaired thermogenesis, obesity, and systemic insulin resistance.\",\n      \"method\": \"Liver-specific transgenic mice; SerpinA1 knockout mice; co-immunoprecipitation (SerpinA1-EphB2 complex); in vitro preadipocyte proliferation and UCP1 assays; metabolic phenotyping\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — receptor identified by Co-IP, transgenic and KO mouse phenotyping, in vitro mechanistic assays, multiple orthogonal methods\",\n      \"pmids\": [\"39532838\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Hepatic A1AT controls the PR3/IL-32γ axis during MASH (metabolic dysfunction-associated steatohepatitis). In MASH, Kupffer cell-derived IL-1β transcriptionally inhibits A1AT expression via HNF4α. Loss of A1AT increases activity of proteinase 3 (PR3), a proinflammatory protease from monocyte-derived Kupffer cells. PR3 cleaves IL-32γ, converting it from an anti-inflammatory/antifibrogenic cytokine into a potent activator of Kupffer cells and failing to prevent hepatic stellate cell activation. In quintuple Serpina1a-e knockout mice, A1AT ablation worsened MASH; A1AT restoration or PR3 inhibition mitigated MASH. A PR3-resistant IL-32γ V104A mutation sustained IL-32γ's protective anti-MASH effects.\",\n      \"method\": \"Quintuple Serpina1a-e knockout mice; fast-food diet MASH model; cytokine array with PR3; IL-32γ V104A mutation; in vivo IL-32γ overexpression; A1AT/PR3 inhibitor treatment; hepatic stellate cell activation assays\",\n      \"journal\": \"Experimental & molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — KO mice, pathway-specific mutations, substrate identification by cytokine array, multiple in vivo and in vitro orthogonal approaches\",\n      \"pmids\": [\"39939782\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CEBPB transcription factor binds the SERPINA1 gene promoter and promotes its transcription, as demonstrated by ChIP and luciferase reporter assays. Overexpression of SERPINA1 in colorectal cancer cells induces nuclear translocation and phosphorylation of the p65 subunit through the PI3K/Akt/NF-κB pathway, promoting cell migration and proliferation. Knockdown of SERPINA1 attenuated PI3K/Akt/NF-κB signaling.\",\n      \"method\": \"ChIP assay; luciferase reporter assay; SERPINA1 overexpression and knockdown; PI3K/Akt/NF-κB pathway analysis; in vitro migration/invasion assays; in vivo liver metastasis model\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and reporter gene confirm transcriptional regulation; pathway placement by OE/KD with signaling readouts\",\n      \"pmids\": [\"38710698\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In trophoblast-derived HTR8/SVneo cells, siRNA knockdown of SERPINA1 revealed marked effects on regulation of the actin cytoskeleton pathway, Slit-Robo signaling, and extracellular matrix organization. Immunoelectron microscopy localized A1AT in villous trophoblasts and in decidual fibrinoid deposits in association with specific extracellular proteins, establishing a role for A1AT beyond protease inhibition in maintaining placental structural integrity.\",\n      \"method\": \"siRNA knockdown in HTR8/SVneo cells; pathway analysis; immunoelectron microscopy; placental proteomics and exon sequencing\",\n      \"journal\": \"BMC medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — siRNA KD with defined pathway readouts, subcellular localization by immunoEM\",\n      \"pmids\": [\"35477570\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In vitro, intra-articular and systemic administration of AAT reversed joint inflammation, nociception, and cartilage degradation in murine arthritis models. SERPINA1 transfection and recombinant AAT protein promoted chondrogenic differentiation in human chondrocytes through activation of PKA-dependent CREB signaling and inhibition of Wnt/β-catenin pathways, establishing a direct mechanistic pathway for AAT's chondroprotective effects.\",\n      \"method\": \"SERPINA1 transfection; recombinant AAT protein treatment; PKA/CREB signaling assays; Wnt/β-catenin pathway analysis; gene expression analysis (col2a1, acan, sox9, mmp13, adamts5); in vivo murine arthritis models\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — transfection and recombinant protein with defined signaling pathway readouts in vitro, confirmed in vivo\",\n      \"pmids\": [\"33788977\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1981,\n      \"finding\": \"Alpha-1-antitrypsin inactivates urinary kallikrein, as demonstrated by an inverse relationship (r=0.84) between kallikrein activity and urinary A1AT concentration in patient samples, establishing renal kallikrein as a substrate/target of A1AT.\",\n      \"method\": \"Clinical urinary proteolytic activity assay (azocasein substrate with kallikrein); immunoassay for urinary A1AT; correlation analysis in 100 hypertensive/proteinuric/hematuria patients\",\n      \"journal\": \"Klinische Wochenschrift\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — correlational clinical data, no direct in vitro enzyme inhibition assay with purified components\",\n      \"pmids\": [\"6973046\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SERPINA1 encodes alpha-1-antitrypsin (A1AT), a 52-kDa serpin whose crystal structure revealed a reactive center loop (RCL) containing Met358 as the elastase 'bait'; upon protease attack, the RCL translocates 71 Å carrying the tethered protease and inducing 37% loss of protease structure to prevent its release—the canonical serpin suicide-inhibitor mechanism. Oxidation of Met351 or Met358 abolishes elastase inhibition, explaining cigarette-smoke inactivation. The Z-variant (E342K) disrupts a salt bridge, causing ER retention and polymerization via the Hrd1/SEL1L/OS-9/GRP94 ERAD pathway; chemical chaperones can partially reverse this ER retention. Beyond elastase inhibition, A1AT directly binds IL-8 to block CXCR1 signaling, inhibits ADAM-17 to maintain FcγRIIIb on neutrophil membranes, inhibits proteinase 3 (PR3) to protect IL-32γ from cleavage in the liver, forms a complex with EphB2 to regulate adipocyte UCP1 and preadipocyte proliferation, undergoes clathrin/SR-BI-mediated endocytosis in lung endothelium for transcytosis to alveolar epithelium, and has its mRNA translation enhanced by NQO1 binding its 3'UTR and regulated by a defined 5'-UTR RNA structure.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"SERPINA1 encodes alpha-1-antitrypsin (A1AT), a secreted serine protease inhibitor (serpin) that serves as a master regulator of extracellular proteolysis, with critical roles in lung protection, liver homeostasis, hematopoietic stem cell niche regulation, and metabolic signaling. A1AT inhibits neutrophil elastase through a suicide-substrate mechanism centered on its reactive center loop residue Met358; structural integrity depends on salt bridges (Glu342–Lys290, Glu263–Lys387), and disruption of the Glu342–Lys290 bridge by the Z variant (E342K) causes misfolding, ER retention, and hepatocyte polymerization leading to liver disease and loss-of-function emphysema [PMID:3289385, PMID:11232197, PMID:12807889]. Beyond its canonical antiprotease role, A1AT functions as a hepatokine that complexes with EphB2 receptor to promote preadipocyte proliferation and UCP1-driven thermogenesis [PMID:39532838], and in the liver it suppresses proteinase 3 activity downstream of HNF4α-mediated transcriptional control, preventing PR3-mediated cleavage of anti-inflammatory IL-32γ and protecting against MASH and fibrosis [PMID:39939782]. A1AT is produced by hepatocytes, alveolar epithelial cells, osteoblasts, and neutrophils, and reaches target tissues via SR-BI- and clathrin-mediated endocytosis and transcytosis across lung endothelium [PMID:19423638, PMID:26092999, PMID:24743137].\",\n  \"teleology\": [\n    {\n      \"year\": 1988,\n      \"claim\": \"Defining the structural basis of serpin function: the reactive center loop around Met358 was established as the inhibitory active site, and two salt bridges (Glu342–Lys290, Glu263–Lys387) were identified as essential for structural integrity, providing a framework to explain how mutations cause disease.\",\n      \"evidence\": \"Biochemical characterization, protein structural analysis, and mutagenesis studies of purified A1AT\",\n      \"pmids\": [\"3289385\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full three-dimensional structure of A1AT–elastase suicide complex not yet resolved at this point\", \"Mechanism of reactive loop insertion into beta-sheet A during inhibition not detailed\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Establishing that A1AT is not only an inhibitor but also a substrate: neutrophil collagenase (MMP-8) cleaves and inactivates A1AT, revealing a proteolytic counter-regulatory mechanism that could compromise antiprotease defense at sites of inflammation.\",\n      \"evidence\": \"In vitro cleavage assay with purified MMP-8 and A1AT, inhibitor controls, Western blotting\",\n      \"pmids\": [\"2173552\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of MMP-8-mediated A1AT inactivation not demonstrated\", \"Cleavage site on A1AT not mapped\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Local production of functional A1AT by alveolar epithelial cells was demonstrated, revising the model that lung protection depends solely on hepatocyte-derived circulating A1AT.\",\n      \"evidence\": \"Northern blot, immunoassay, and elastase–A1AT complex formation in A549 and rat type-II pneumocytes\",\n      \"pmids\": [\"8013628\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Quantitative contribution of locally vs. systemically produced A1AT to lung defense not determined\", \"Regulation of alveolar epithelial SERPINA1 expression not characterized\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Neutrophils were shown to store and co-secrete A1AT alongside neutrophil elastase upon degranulation, establishing an intrinsic feedback mechanism that limits proteolytic damage at the site of release.\",\n      \"evidence\": \"Immunofluorescence, flow cytometry, 35S-methionine pulse-chase with anti-A1AT immunoprecipitation, fMLP stimulation of neutrophils\",\n      \"pmids\": [\"8970377\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Subcellular compartment of A1AT storage in neutrophils not definitively identified\", \"Whether neutrophil-derived A1AT is quantitatively sufficient for local protection remains unclear\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"The molecular pathology of Z-A1AT was consolidated: the E342K mutation causes misfolding, polymerization, and ER retention in hepatocytes, directly linking gain-of-toxic-function liver disease and loss-of-function lung disease to a single structural defect.\",\n      \"evidence\": \"Cell biology studies of mutant protein folding, ER retention assays, biochemical polymer characterization\",\n      \"pmids\": [\"11232197\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise polymerization interface (domain-swap vs. loop-sheet mechanism) remained debated\", \"Cellular quality control pathways disposing of Z-polymers not fully mapped\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"A druggable surface hydrophobic cavity on beta-sheet A was identified as a critical determinant of polymerization, and cavity-filling mutations (T114F, G117F) retarded polymerization without compromising inhibitory function, opening a path to anti-polymerization therapeutics.\",\n      \"evidence\": \"Site-directed mutagenesis, thermal stability and polymerization assays, Xenopus oocyte secretion system\",\n      \"pmids\": [\"12807889\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether cavity-filling mutations rescue Z-A1AT secretion in mammalian hepatocytes not shown\", \"Small-molecule occupancy of this cavity not yet demonstrated\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"A1AT was identified as a potent inhibitor of hematopoietic stem cell mobilization, expanding its functional repertoire beyond antiprotease activity in the lung to regulation of the bone marrow niche via serine protease inhibition.\",\n      \"evidence\": \"In vivo Serpina1 administration before IL-8/G-CSF mobilization in mice, heat-inactivation and antibody-neutralization controls\",\n      \"pmids\": [\"16432201\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific serine protease target(s) in the BM niche not identified\", \"Relevance to human HSC mobilization not tested\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"The trafficking pathway of A1AT to its site of action was resolved: clathrin-mediated endocytosis (not caveolae) mediates A1AT uptake by lung endothelial cells, and osteoblasts were identified as the primary source of Serpina1 in bone marrow.\",\n      \"evidence\": \"Clathrin vs. caveolae inhibitors, co-IP with clathrin heavy chain, cigarette smoke exposure (endothelial cells); BM fraction isolation, qRT-PCR, Western blot, IHC (osteoblasts)\",\n      \"pmids\": [\"19423638\", \"19375654\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor mediating clathrin-dependent A1AT endocytosis not yet identified at this point\", \"Signals directing A1AT to clathrin-coated pits unknown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"A1AT was shown to undergo active transcytosis across polarized lung endothelial cells to reach epithelial cells, establishing a vectorial transport mechanism that delivers circulating A1AT to the alveolar compartment.\",\n      \"evidence\": \"Transwell co-culture, time-lapse confocal microscopy, two-photon intravital microscopy in mice, Golgi pathway inhibition\",\n      \"pmids\": [\"24743137\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular cargo receptor for transcytosis not identified\", \"Rate-limiting step in transcytosis not defined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"SR-BI was identified as a receptor mediating A1AT endocytosis by pulmonary endothelial cells, with Scarb1-null mice showing reduced lung A1AT content and impaired anti-inflammatory effects of A1AT supplementation.\",\n      \"evidence\": \"SR-BI immunoprecipitation, SCARB1 knockdown, neutralizing antibody, ligand competition, TEM with colloidal gold, Scarb1 KO mice\",\n      \"pmids\": [\"26092999\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether SR-BI mediates transcytosis or only endocytosis not distinguished\", \"Binding interface between A1AT and SR-BI not mapped\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Post-transcriptional regulation of A1AT was revealed: NQO1 binds SERPINA1 mRNA 3′UTR and coding region to enhance translation without affecting mRNA stability, and NQO1-KO mice have reduced hepatic/serum A1AT and increased elastase activity.\",\n      \"evidence\": \"RIP-chip, biotin pulldown, polysome profiling, luciferase reporter, NQO1-KO mice\",\n      \"pmids\": [\"27515817\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether NQO1's redox enzymatic activity is coupled to its RNA-binding function unknown\", \"Other RNA-binding proteins regulating SERPINA1 translation not surveyed\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Natural coding variation (V213A) was shown to modulate A1AT–elastase interaction specifically in the presence of lipoproteins, with structural flexibility differences measured by H/D exchange, revealing that the lipid environment tunes A1AT function.\",\n      \"evidence\": \"Microscale thermophoresis binding assay in lipoprotein-containing vs. lipid-free plasma, hydrogen/deuterium exchange mass spectrometry\",\n      \"pmids\": [\"28265093\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of lipoprotein species mediating the effect not determined\", \"Clinical impact of V213A variant on lung disease progression not resolved mechanistically\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"The SERPINA1 5′-UTR was shown to fold into a structured multi-helix domain that promotes cap-dependent translation by maintaining AUG accessibility, establishing that global RNA architecture—not just local structure—governs SERPINA1 translational output.\",\n      \"evidence\": \"SHAPE RNA structure probing, systematic mutagenesis, cap-dependent translation reporter assays\",\n      \"pmids\": [\"36107773\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether 5′-UTR structure is regulated by trans-acting factors in vivo unknown\", \"Interaction between 5′-UTR structure and NQO1-mediated translational control not examined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"A1AT was established as a hepatokine that signals through EphB2 receptor to drive preadipocyte proliferation and adipose tissue browning, with liver-specific transgenic mice showing increased energy expenditure and knockout mice displaying obesity and insulin resistance.\",\n      \"evidence\": \"Co-immunoprecipitation of A1AT–EphB2 complex, liver-specific transgenic and knockout mouse models, UCP1 expression, metabolic phenotyping\",\n      \"pmids\": [\"39532838\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Binding site on EphB2 and whether A1AT acts as a ligand or co-receptor not defined\", \"Whether the metabolic function requires A1AT's antiprotease activity not tested\", \"Relevance to human metabolic disease not validated\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"A liver-protective circuit was delineated: HNF4α drives SERPINA1 transcription in hepatocytes; A1AT inhibits proteinase 3 (PR3) from monocyte-derived Kupffer cells; PR3 cleaves IL-32γ into a pro-inflammatory fragment; loss of A1AT unleashes PR3 activity, converting IL-32γ from antifibrotic to profibrotic and driving MASH/fibrosis.\",\n      \"evidence\": \"Quintuple Serpina1a-e KO mice, A1AT restoration and PR3 inhibition, IL-32γ V104A cleavage-resistant mutant, HNF4α transcription factor analysis, cytokine array\",\n      \"pmids\": [\"39939782\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether IL-1β–HNF4α–A1AT axis operates in human MASH liver biopsies not confirmed\", \"Other PR3 substrates contributing to fibrosis not surveyed\", \"Therapeutic potential of PR3 inhibition vs. A1AT supplementation not compared\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of the A1AT–EphB2 signaling complex, whether A1AT's metabolic and antiprotease functions are mechanistically separable, the identity of the serine protease target mediating HSC mobilization inhibition, and whether the polymerization mechanism in vivo follows a domain-swap or loop-sheet pathway.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Structural model of A1AT–EphB2 complex lacking\", \"No separation-of-function mutant distinguishing antiprotease vs. signaling roles\", \"In vivo polymerization mechanism not definitively resolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 6, 12, 18]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [17]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [2, 3, 6, 9, 12]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [4, 5]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [7, 10]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 3, 6, 18]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [17, 21]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [17]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0, 4, 5]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [4, 18]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"ELANE\",\n      \"EPHB2\",\n      \"SCARB1\",\n      \"NQO1\",\n      \"PRTN3\",\n      \"CLTC\",\n      \"MMP8\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"SERPINA1 encodes alpha-1-antitrypsin (A1AT), a secreted serpin-family serine protease inhibitor that functions as the principal physiological inhibitor of neutrophil elastase and serves broader roles in immune regulation and metabolic homeostasis. A1AT employs a suicide-inhibitor mechanism in which its reactive center loop, with Met358 as the protease 'bait', is cleaved by the target protease, triggering a 71 Å translocation of the loop that carries the covalently tethered protease to the opposite pole of the molecule, distorting its active site and preventing release [PMID:11057674, PMID:6332197]. Beyond elastase inhibition, A1AT directly binds IL-8 to block CXCR1-mediated neutrophil chemotaxis, inhibits ADAM-17 to preserve Fcγ RIIIb on neutrophil membranes [PMID:21060150], inhibits proteinase 3 to protect anti-inflammatory IL-32γ in the liver [PMID:39939782], and acts as a hepatokine that complexes with EphB2 to promote adipocyte UCP1 expression and energy metabolism [PMID:39532838]. The Z variant (Glu342Lys) disrupts a critical salt bridge, causing ER retention, polymerization via Hrd1/SEL1L/OS-9/GRP94-dependent ERAD, hepatocyte inclusion body disease, and reduced circulating A1AT predisposing to emphysema [PMID:18264092, PMID:6093867, PMID:12464660].\",\n  \"teleology\": [\n    {\n      \"year\": 1982,\n      \"claim\": \"Establishing A1AT as the primary tissue scavenger of leukocyte elastase and linking the common S and Z deficiency variants to emphysema pathogenesis answered the fundamental question of what protease–antiprotease imbalance drives lung destruction.\",\n      \"evidence\": \"Protein sequence determination and variant analysis in human plasma\",\n      \"pmids\": [\"7045697\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of inhibition unknown at atomic level\", \"Molecular basis of Z and S variant dysfunction not yet resolved\"]\n    },\n    {\n      \"year\": 1983,\n      \"claim\": \"The Pittsburgh variant (Met358→Arg) demonstrated that reactive center identity dictates protease specificity, converting A1AT from an elastase inhibitor to a thrombin inhibitor and establishing the bait-residue paradigm for the entire serpin family.\",\n      \"evidence\": \"Characterization of a naturally occurring active-site mutation in a patient with fatal bleeding disorder\",\n      \"pmids\": [\"6604220\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How the conformational change upon cleavage traps the protease was structurally undefined\"]\n    },\n    {\n      \"year\": 1984,\n      \"claim\": \"Determination of the crystal structure of cleaved A1AT and the complete gene/cDNA sequence revealed the three β-sheet / eight α-helix architecture, placed Glu342 at a strategic position for the conformational rearrangement (explaining Z-variant pathology), and defined the S-variant as Glu264→Val.\",\n      \"evidence\": \"X-ray crystallography at 3 Å (two crystal forms) and cDNA/gene sequencing\",\n      \"pmids\": [\"6332197\", \"6093867\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Native (uncleaved) structure not yet solved\", \"Atomic mechanism of loop translocation unknown\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"The native-form crystal structure at 2.9 Å showed the reactive center loop in a canonical β-strand conformation without insertion into the molecule, supporting a two-stage inhibition mechanism and providing a structural basis for aberrant polymerization.\",\n      \"evidence\": \"X-ray crystallography at 2.9 Å resolution\",\n      \"pmids\": [\"8756325\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full serpin–protease complex structure not yet available\", \"Polymer interface not resolved atomically\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Three simultaneous advances resolved core mechanism: (1) the serpin–protease complex crystal structure showed the 71 Å loop translocation drags and distorts the tethered protease; (2) mutagenesis/MS established that oxidation of either Met351 or Met358 abolishes elastase inhibition; (3) chemical chaperone PBA rescued Z-A1AT secretion in cells and PiZ mice.\",\n      \"evidence\": \"Crystal structure of serpin–protease complex; site-directed mutagenesis with mass spectrometry and elastase assays; PBA treatment in cell culture and PiZ transgenic mice\",\n      \"pmids\": [\"11057674\", \"10867014\", \"10677536\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of oxidative inactivation at physiological oxidant concentrations not fully tested\", \"Whether PBA corrects polymerization or simply accelerates folding kinetics unresolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identification of a druggable hydrophobic cavity on β-sheet A (Thr114, Gly117) that, when filled by mutagenesis, stabilized the molecule and retarded polymerization without affecting inhibitory activity, provided the first structure-based target for anti-polymerization small molecules.\",\n      \"evidence\": \"Site-directed mutagenesis with thermal stability, polymerization kinetics, and Xenopus oocyte secretion assays\",\n      \"pmids\": [\"12807889\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No small-molecule ligand for the cavity identified\", \"Effect on Z-variant polymerization in hepatocytes not tested\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Mapping Z-A1AT degradation onto the Hrd1/SEL1L/OS-9/GRP94 ERAD pathway answered how misfolded Z-A1AT is targeted for proteasomal destruction in the ER, explaining the gain-of-toxic-function hepatic disease.\",\n      \"evidence\": \"Co-immunoprecipitation and RNAi knockdown of ERAD components with Z-A1AT degradation assays in mammalian cells\",\n      \"pmids\": [\"18264092\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Contribution of autophagy vs. ERAD to Z-polymer clearance not fully delineated\", \"Whether ERAD saturation triggers the inflammatory hepatic response is unclear\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Discovery that A1AT is internalized by lung endothelial cells via clathrin-mediated endocytosis—and that cigarette smoke inhibits this uptake—established that delivery of circulating A1AT to the lung interstitium requires active receptor-mediated transcytosis rather than passive diffusion.\",\n      \"evidence\": \"Pharmacological endocytic pathway inhibition, co-IP with clathrin heavy chain, in vivo mouse cigarette smoke exposure\",\n      \"pmids\": [\"19423638\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor identity for clathrin-dependent uptake not identified at this stage\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Demonstration that A1AT directly binds IL-8 to block CXCR1 signaling and independently inhibits ADAM-17 to maintain Fcγ RIIIb on neutrophils revealed two protease-independent anti-inflammatory pathways, extending A1AT's function beyond elastase inhibition.\",\n      \"evidence\": \"Direct binding assays, ADAM-17 enzymatic inhibition, flow cytometry for Fcγ RIIIb; human AAT-deficient patient samples with augmentation therapy\",\n      \"pmids\": [\"21060150\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of A1AT–IL-8 interaction unresolved\", \"Whether ADAM-17 inhibition is direct active-site engagement or allosteric unclear\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identification of SR-BI as an endothelial receptor for A1AT uptake, confirmed by knockout mouse phenotype, resolved the receptor question for pulmonary transcytosis and linked A1AT biology to lipoprotein receptor pathways.\",\n      \"evidence\": \"Co-IP, siRNA knockdown, competitive ligand blocking, Scarb1 KO mice, immunogold EM\",\n      \"pmids\": [\"26092999\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether SR-BI is the sole receptor or acts redundantly with other receptors not resolved\", \"Caveolae vs. clathrin contribution to SR-BI-mediated uptake not fully dissected\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"NQO1 was identified as an RNA-binding protein that binds the SERPINA1 3′-UTR and coding region to enhance A1AT translation, revealing a post-transcriptional regulatory axis confirmed by NQO1-KO mice having reduced serum A1AT and increased elastase activity.\",\n      \"evidence\": \"RNP immunoprecipitation, biotin pulldown, polysome profiling, luciferase reporters, NQO1-KO mice\",\n      \"pmids\": [\"27515817\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How NQO1's oxidoreductase activity relates to its RNA-binding function unknown\", \"Other trans-acting factors regulating SERPINA1 mRNA not characterized\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Systematic SHAPE probing and mutagenesis of the SERPINA1 5′-UTR revealed a structured RNA domain that optimizes cap-dependent translation by maintaining accessibility at the initiation site, adding a cis-regulatory layer to A1AT translational control.\",\n      \"evidence\": \"SHAPE structure probing, systematic 5′-UTR mutagenesis, cap-dependent translation reporter assays\",\n      \"pmids\": [\"36107773\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of 5′-UTR structure under stress conditions not tested\", \"Whether disease-associated variants affect 5′-UTR folding unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"A1AT was shown to function as a hepatokine that complexes with EphB2 to induce adipocyte UCP1 expression and preadipocyte proliferation, establishing an endocrine role in energy metabolism beyond its canonical antiprotease function.\",\n      \"evidence\": \"Co-IP of A1AT–EphB2 complex; liver-specific transgenic and KO mice with metabolic phenotyping; in vitro adipocyte assays\",\n      \"pmids\": [\"39532838\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and structural basis of A1AT–EphB2 complex unknown\", \"Whether this function requires serpin inhibitory activity is untested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identification of the PR3/IL-32γ axis as a hepatic target of A1AT in MASH revealed that Kupffer cell IL-1β suppresses A1AT expression via HNF4α, enabling PR3 to cleave protective IL-32γ, which links A1AT deficiency to steatohepatitis progression.\",\n      \"evidence\": \"Quintuple Serpina1a-e KO mice, fast-food diet MASH model, PR3-resistant IL-32γ mutant, A1AT restoration experiments\",\n      \"pmids\": [\"39939782\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relevance to human MASH with normal A1AT genotype not established\", \"Whether PR3 inhibition fully recapitulates A1AT restoration unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the atomic structure of A1AT polymers; the structural basis of the A1AT–IL-8 and A1AT–EphB2 interactions; the mechanism by which NQO1's RNA-binding and oxidoreductase activities are coordinated; and whether A1AT's metabolic hepatokine function is serpin-activity dependent or represents an entirely independent molecular surface.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Polymer interface not resolved at atomic level despite decades of effort\", \"No crystal structure of A1AT–EphB2 or A1AT–IL-8 complex\", \"Therapeutic targeting of the β-sheet A cavity not validated in human trials\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 2, 4, 6, 7]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [6, 7, 15]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [23]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [1, 11, 12, 15, 18, 19, 23]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [8, 13, 14, 16]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [12]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [17, 21]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [15, 19, 31]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [6, 16]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [30]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [19, 30, 32]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [13, 31]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"ELANE\",\n      \"CXCL8\",\n      \"ADAM17\",\n      \"EPHB2\",\n      \"PRTN3\",\n      \"NQO1\",\n      \"SCARB1\",\n      \"CLTC\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}